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PREFACE 
This thesis is divided into three main sections. The 
first part (Chapter II) is a literature review of 
time-resolved fluoroimmunochemical determinations. The next 
section (Chapter III) is a dicussion of phase-resolved 
fluorescence spectroscopy {PRFS) and a review of 
phase-resolved fluoroimmunochemical determinations. The 
following two chapters, IV and V, describe the approaches 
that were taken to develop a simplified and improved 
phase-resolved fluoroimmunoassay for phenobarbital in order 
to illustrate the applicability of PRFS to the determination 
of haptens. 
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Immunochemical determinations belong to a broad class 
of analytical techniques called "binding assays". These 
techniques are defined as "any procedure in which quanti-
tation of a material depends on the progressive saturation 
of a specific binder by that material and the subsequent 
determination of its distribution between bound and free 
phases" (1). In an immunochemical determination, the binder 
is an antibody (Ab) and the material being quantified is its 
antigen (Ag) • Immunochemical determinations are very power-
ful analytical techniques due to their combination of high 
selectivity, low detection limits and wide applicability. 
They currently allow for the determination of femtornolar 
concentrations of analytes in highly complex samples. 
The distribution of· analyte between bound and free 
phases is usually followed by attaching a label, detectable 
by some physiochemical means, to either the antigen (Ag*) or 
antibody (Ab*). Labelled-antigen methods are called 
"i~munoassays" and labelled-antibody methods are usually 
called "immunometric assays". The bound and free phases are 
usually physically separated before the label is measured; 
1 
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however, if the signals of the bound and free labelled com-
pounds are sufficiently different no separation step is 
necessary. Determinations requiring a separation step are 
"heterogeneous" and those that do not are "homogeneous". 
The label can be any material which can be measured pre-
cisely and accurately in very small quantities. Typical 
labels include radioisotopes, enzymes and fluorophores. 
Radioactive isotopes are the most widely employed 
labels in immunochemical determinations. In recent years 
legal, social and logistical objections to their use have 
been raised. The use of radioisotopes involves potential 
environmental and health hazards, mainly in the preparation 
of the labelled reagent but also in its handling and dis-
posal. The labelled reagent also has a relatively short 
shelflife due to the nature of the label. On the other 
hand, radioisotopes are not affected by variations in the 
chemical and physical microenvironments; the instrumentation 
used is reliable, relatively inexpensive and now widely 
available; and the label has a very high signal-to-noise 
ratio. Alternative labels generally have higher limits of 
detection and/or are not as easy to use except for the 
avoidance of radioactivity. They are widely applied to 
those analytes not requiring low detection limits or to 
determinations in which qualitative rather than quantitative 
results are desired. 
Fluorescent labels are relatively inexpensive and have 
a reasonably long shelflife. The fluorescence measurement 
can usually be accomplished quickly and easily. The main 
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limitation of fluorescent labels is that many compounds 
present in biological fluids can cause problems in the 
measurement of the fluorescence of a fluorophore. These 
problems include light scattering, endogenous fluorophores, 
inner filter effects and quenching. The fluorophores most 
frequently used as labels in immunochemical determinations 
include fluorescein, the rhodamines, umbelliferone, fluores-
camine and rare earth metal chelates. The fluorophore most 
widely used at the present time is fluorescein, which has a 
high molar absorptivity (N9x104 M-lcm-1) in the vis- ible 
region of the electromagnetic spectrum and a quantum yield 
approaching 1.00. It also has high photo-stability and 
chemical stability. Its main drawback is that it is very 
sensitive to background interferences, scattering from the 
sample and concentration quenching. 
Immunochemical determinations employing fluorescent 
labels have been gaining widespread usage. This is due to 
the high sensitivity of fluorescence measurement and the 
sensitivity of the fluorescent label to changes in its chem-
ical microenvironment. Because of the sensitivity to 
changes in its environment, simple, rapid heterogeneous and 
homogeneous fluoroimmunochemical determinations are pos-
sible. Determinations based on changes in fluorescence 
intensity, energy transfer, polarization and fluorescence 
lifetimes have been reported (2-5). Two different tech-
niques have been developed to take advantage of changes in 
fluorescence lifetimes in fluoroimmunochemical determina-
4 
tions. One is based upon time-resolved spectroscopy and the 
other on phase-resolved fluorescence spectroscopy. 
In time-resolved spectroscopy, pulsed light is used to 
excite the sample and the fluorescence decay is monitored. 
When a fluorophore is excited by pulsed light, fluorescence 
is emitted following each pulse with an intensity which 
decays at a rate related to the excited-state lifetime of 
the emitting species. An electronically-gated detection 
system can be used to measure photons at any time interval 
after the excitation pulse has decayed to an undetectable 
level. Time-resolved fluoroimmunoche~ical determinations, 
based upon time-resolved methods of eliminating background 
fluorescence, employ fluorescent +abels with lifetimes above 
100 ns. The labels are usually some type of rare earth 
chelate and the determinations are usually heter- ogeneous. 
Two different commercially available time-resolved fluoro-
immunoassay systems have been developed. Chapter II is a 
critical review of time-resolved fluoroimmunochemical 
determinations, including a discussion of the labels and 
instrumentation developed for use in them. 
In phase-resolved fluorescence spectroscopy, sinu-
soidally-modulated light is used to excite the fluorescent 
sample. The resulting fluorescence emission is also sinu-
soidally modulated but is phase-shifted and demodulated with 
respect to the excitation beam. The emission signal, 
measured with a phase-sensitive detector, is dependent on 
the modulation frequency, the excitation and emission wave-
lengths, and the intensity, lifetime and concentration 
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characteristics of the emitting specie(s). ·The phase-
resolved fluoroimmunochemical determinations that have been 
reported used fluorescent labels, fluorescein and two rhod-
amines, with short lifetimes (< 5 ns). These determin-
ations were all homogeneous systems and were based on life-
time differences between the free and bound labelled 
species. Phase-resolved fluoroimmunochemical determinations 
are the only immunochemical determinations that use fluor-
escence lifetime selctivity as the basis of homogeneous 
detection. Chapter III contains a brief discusssion of the 
theory of phase-resolved fluorescence spectroscopy and a 
review of phase-resolved fluoroimmunochemical 
determinations. 
The first phase-resolved immunochemical determination 
was developed for phenobarbital (6) and was based on very 
small changes in the intensity (< 10%) and lifetime 
(100 ps) of fluorescein-labelled phenobarbital when it was 
bound by the anti-phenobarbital antibody. Because of the 
very small changes in the fluorescence signal, the data 
collection and analysis was fairly complicated and time-
consuming. It was also not very amenable to automation. 
The reagents were purchased in the form of a heterogeneous 
fluoroimmunoassay kit from a company that subsequently went 
out of business. 
There was a need to simplify and improve the pheno-
barbital immunoassay, in order to better demonstrate the 
feasability of the phase-resolved approach to fluoroimmun-
assay of small molecules. The work presented in this thesis 
describes various approaches that were taken towards this 
goal. The studies can be divided into two main categories 
as follows: 
1) Studies of the effects of organized media on the 
6 
fluorescence of fluorescein-labelled phenobarbital and 
antibody-bound labelled phenobarbital. The effects of 
various surfactants and cyclodextrins were evaluated and 
compared, with the idea that they might improve the dis-
crimination between the free and antibody-bound· labelled 
phenobarbital. This work is presented in Chapter IV. 
2) Studies of the optimization of experimental con-
ditions with respect to the various reagents used in the 
fluoroimmunoassay. In order not to eliminate the depen-
dence on commercially-available kits, phenobarbital, 
fluorescein-labelled phenobarbital and anti-phenobar-
bital antibodies were obtained individually from com-
mercial sources or synthesized here at Oklahoma State 
University. Thus, both reagent concentrations and 
instrumental conditions could be optimized. Effects of 
several different antibody preparations were .studied and 
compared. Also, a different experimental approach to 
data collection and analysis was taken in order to fa-
cilitate the implementation of a flow system. These 
studies are presented in Chapter v. 
CHAPTER II 




The first immunoassay was reported by Yalow and Berson 
(6) in 1960. They used 134I-labelled antigens to develop a 
radioimmunoassay for insulin. In a labelled-antigen 
immmunoassay (Figure 1), the labelled and unlabelled antigen 
compete for a limiting amount of antibody. The amount of 
labelled antigen bound by the antibody is controlled by the 
law of mass action. As the amount of unlabelled antigen in 
the sample increases, the amount of labelled-antigen bound 
to the antibody decreases. Thus the amount of labelled-
antigen present in the bound phase is inversely proportional 
to the amount of antigen (analyt~) in the sample. If the 
exact concentrations of labelled antigen and antibody and 
the affinity constant for the system are known, then the 
analyte concentration could be determined by calculation. 
In practice, a calibration curve of a series of antigen· 
standards is almost always needed. 
Miles and Hale (7) introduced the first "immunometric 





1 M•o~~· .. 
~·Antigen Measure Fluorescence 
I Antibody 0 Label 
Figure 1. Schematic Representation of an Immunoassay 
Procedure. Adapted from Simonsen, M.G. 
In Nonisotopic Alternatives to Radio-
immunoassay: Principles and xpplications; 
Kaplan, L.A.; Pesce, A.J., Eds.; Marcel 
Dekker, Inc.: New York, 1981; p. 1. 
antibody. The antigen was allowed to react with a fixed, 
excess amount of labelled antibody. Either the 
antigen-labelled antibody complex or the free labelled 
antibody may be determined. 
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Immunometric determinations (Figure 2), are divided 
into two main variations. In the first, the antigen in the 
sample competes with antigen immobilized on a solid phase 
for the labelled antibody. After a separation step, the 
amount of labelled antibody in one of the two phases is 
measured and the amount of analyte is determined from a 
calibration curve. The amount of labelled antibody in the 
solid phase is inversely proportional to the amount of 
analyte. This type of immunometric determination is also 
known as "one-site" since only one antigenic determinant is 
needed. In contrast, the other type of immunometric 
determination uses an antibody solid phase in addition to a 
labelled antibody. In this noncompetitive, "two-site" 
technique, the analyte is incubated with an excess of solid 
phase antibody and an excess of labelled antibody. The 
"two-site" immunometric determinations is are divided into 
"one-step" and "two-step" methods, depending on the number 
of incubation steps used. After the immunochemical 
reactions have occured, the solid phase is separated from 
the reaction medium. The amount of labelled antibody in the 
solid phase is directly proportional to the amount of 
antigen in the sample. The concentration of analyte is 
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Figure 2. Schematic Representation of an Immunometric Procedure. 








two antibodies do not bind to separate antigenic 
determinants, or if the number of molecules with binding 
sites to only one of the antibodies is high, then the 
analyte should first be allowed to react with the solid 
phase antibody and then washed before the labelled antibody 
is added ( a "two-step" method) • The "two-site" 
immunometric determination is also known by the descriptive 
term "sandwich immunoassay". 
Sensitivity, Detection limits 
and Selectivity 
Sensitivity and Detection Limits 
In clinical chemistry and biochemistry journals the 
terms sensitivity and detection limit are often misused in 
the eyes of analytical chemists. The American Chemical 
Society Committee on Environmental Improvement defines 
detection limit as "the lowest concentration of analyte that 
the analytical process can reliably detect" (9). They 
recommend that the detection limit be located at three 
standard deviat.:Lons above the blank signal. It should be 
expressed in concentration units derived from the 
calibration curve. This method gives a 7% risk of false 
negatives and false positives. The sensitivity of a method 
is defined as " the ratio of change in instrumental response 
to the change in analyte concentration, i.e., the slope of 
the calibration .curve." Note that detection limit and 
sensitivity are not interchangable. Most papers on 
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immunochemical determinations use some seemingly arbi-
trarily-chosen value as the detection limit and then proceed 
to use sensitivity as a synonym for detection limit. Some 
of this confusion becomes more understandable in light of 
the International Federation of Clinical Chemistry (IFCC) 
definitions of sensitivity and detection limit (10). They 
define sensitivity as " the ability of an analytical method 
to detect small quantities of the measured component." They 
state further that sensitivity has no numerical value. 
Detection limit is defined as "the smallest single result, 
which with a stated probability (commonly 95%), can be 
distinguished from a suitable blank." The limit of 
detection, according to the IFCC, may be either a 
concentration or an amount. The confusion that results from 
these radically different definitions of sensitivty can best 
be illustrated by Figure 3, taken from Ekins (8), who states 
that "the definition of sensitivity in terms of lower limit 
of detection has now been both universally and formally 
accepted". In this review the ACS definitions of 
sensitivity and limit of detection shall be used; 
alternative usages of these words have been translated into 
the appropriate terminology. 
A significant improvement in the detection limit is one 
of the principal advantages of noncompetitive immunometric 
determinations over immunoassays (and competitive immuno-
metric determinations). This improvement in the detection 
limits, according to Ekins and coworkers (8,11,12), is due 
R 
R 
'A' more sensitive 
(Berson and Yalow) 
D 
·e· more sensitive 
(Ekins and Newman) 
D 
Assav dose-response curves for two assavs (A and RJ are shown. 
The Berson/Yalow concept of s~nsitivity defines assay A as of gre~ter si>nsitivitv. Ekin.~ 
et al (8-1 ,iefine assay B as more sensitive since the mndom error in the zero dose 
measurement" (an) i.e. the lower limit of detection, is smaller. cr R represents the 
random i>rror in the response variable (R) at zero dose. 
Figure .., .::> • Sensitivity vs. Detection Limit for an 
Immunoassay. From Reference (8). 
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to the differences in the optimal reagent concentrations for 
the two types of immunochemical determinations. In any 
immunochemical determination, the overall detection limit of 
the method is influenced by the equilibrium constant of the 
immunochemical reaction, the detectability of the label, the 
extent of misclassification of the labelled reagent (bound 
versus free) , and the precision of the required reagent 
manipulations (12). However, the relative importance of 
these factors differs significantly as a result of the 
contrasting amounts of antibody which are optimal in each 
type of determination. 
Consider an ideal system in which the antibodies show 
negligible nonspecific binding and the label has an infinite 
detectability. In an immunoassay, the optimal antibody 
concentration tends toward zero when either the bound or 
free fraction of labelled antigen is measured. In a 
noncompetitive immunometric determination, the optimal 
antibody concentration tends toward zero when the free 
labelled antibody is measured and toward infinity when the 
bound labelled antibody is measured. In an immunoassy, 
because the optimal Ab concentration approaches zero, the 
equilibrium constant, Keq' of the immunochemical reaction is 
the dominant factor in determining the extent of reaction 
and thus is a major constraint on the ultimate detection 
limit of the method. The precision of the reagent 
manipulations is also very critical. The ultimate detection 
limit is defined by Ekins (8) as the relative error in the 
signal of the analyte blank (o:R/R) divided by K • The eq 
relative error is composed of an "experimental" error 
component (£) and a signal measurement component, where CC.. 
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is the error due to reagent and sample manipulations. Since 
the label has an "infinite detectability", the signal 
measurement component of the relative error should be 
essentially equal to zero. Thus, the detection limit is 
reduced to ~/Keq• Ekins assumes that € is limited in 
practice to approximately 1%~ Equilibrium constants of 
antigen-antibody reactions are seldom higher than 1012 
liters/mole (1). Thus the ultimate detection limit is 
around 10-14 M regardless of the choice of label. The best 
detection limits reported in the literature for this type of 
determination are around 10-10 M (12). In a noncompetitive 
immunometric determination where the amount of bound 
labelled reagent is measured, Keq is of lesser importance 
because an excess of labelled antibody is used. However, 
using an excess of Ab* also increases the nonspecific 
.binding. The optimal concentration of Ab* is dependent upon 
both the Keq and the fractional nonspecific binding of .Ab*. 
Hence, high antibody binding strength is advantageous but of 
lesser importance than in an immunoassay. When larger 
amounts of antibody are used, the pipetting precision is 
also improved. 
Ekins and collegues (8) state that the ultimate limit 
of detection is defined by: a) the relative error of the 
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analyte blank signal ( °R./R) , b) the fractional non-specific 
binding of the antibody (k), and c) the equilibrium 
constant. The relative error in the analyte blank signal is 
equal to o;/n.s.b. , the error in the estimate of the 
non-specifically bound (n.s.b.) antibody. The resulting 
expression of the detection limit is given by 
( 1) 
Keq (n.s.b.) 
They assume that a;/n.s.b. and k are equal to 1% and that 
Keq is once again equal to 1012 liters/mole. The minimum 
detection limit is then equal to 10-16 M, which is two 
orders of magnitude lower than the minimum detection limit 
of an immunoassay. 
In the above calculations it was assumed that the 
detectability of the label was infinite. In actual practice 
this is not the case. The most commonly used radioisotope 
125I, has a detection limit of ,.....107 molecules/ml or 2x10-14 
M (8). This is of the same order of magnitude as the 
minimum detection lim~t of an immunoassay. The use of a 
label with a lower detection limit than 125I in an 
immunoassay would not yield much benefit in terms of 
detection limits. However, in a noncompetitive immunometric 
determination a gain of approximately two orders of 




Most substances with molecular weight greater than 5000 
can elict an immune response (13). Substances with a 
smaller molecular weight usually need to be coupled to a 
large carrier molecule to stimulate the immune system. 
Substances that elicit an immune response are known as 
antigens. Small nonimmunogenic antigens are called haptens. 
Antibodies belong to a type of protein called 
immunoglobulins, which are divided into five classes. Most 
immunochemical determinations make use of immunoglobulin G 
(IgG), which has a molecular weight of 160,000 and 
consists of four peptide chains held together by disulfide 
bonds·. The two longer heavy chains and the two shorter 
light chains are joined to form a Y-shaped structure, as 
seen in Figure 4. The N-terminal halves of each chain are 
variable in aminoacid sequence while the C-terminal halves 
are constant. The N-terminal region of one heavy and one 
light chain form a binding site that makes a complementary 
fit with the antigen. 
The immune response will result in the production of 
large numbers of antibody molecules with slightly different 
variable regions. Some will fit the antigen closely and 
have a high binding strength while others will fit less 
closely and consequently have a lower binding strength. 
Cross-reactants are substances, usually with some close 
structural similarity to the antigen, that bind to the same 
antibody. Antibody binding strength is the result of the 
Schematic representation of antibody (immunoglobulin G) structure and 
some aspects of the immune response. An immunogenic molecule (center) has anti-
genic determinants A and B, and hapten groups (H) are covalently attached. The 
response to the immunogen results in the formation of Y-shaped antibody molecules 
whose variable sequence regions (shaded) form binding sites specific for A, B, or H. 
Antibodies against H will bind the free (nonimmunogenic) hapten (top). A structurally 
related hapten (G) will also bind (cross-react) with such antibodies (bottom). 
Figure 4. Schematic Representation of Antibody 
Structure and Some Aspects of Immune 
Response. From Reference (4). 
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combined effects of all the noncovalent interactions between 
the antigen and the binding site (4). Most antibodies have 
association constants between 106 - 1012 liter/mole (4). 
Immunochemical determinations generally use antibodies with 
constants in excess of 109 liter/mole (1). Non-ipecificity 
in an immunochemical determination is mainly due to two 
factors, cross-reactants and other substances which affect 
the Ab/Ag equilibrium constant. The relative effects of 
these two factors depend upon the type of immunochemical 
determination employed. 
The effect of cross-reactants is more pronounced in the 
case of noncompetitive immunometric determinations than in 
the case of immunoassays and competitive immunometric 
determinations (12). Cross-reactants compete with the 
analyte for the antibody binding sites. In an immunoassay, 
the strength of the cross-reactant relative to the analyte 
with respect to the antibody binding site is approximately 
equal to the ratio of their equilibrium constants (11). If 
the equilibrium constant of the antibody/antigen reaction is 
large, the effect of most cross-reactants is negligible. In 
a noncompetitive immunometric determination, the large 
excess of antibody lessens the effect of differences in 
binding strength. Equal amounts of analyte and cross-
reactant tend to give equal responses; this effect can be 
reduced by immunopurification of the antibody or by use of 
the sandwich method (12). 
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Substances which alter the equilibrium constant of the 
immunochemical reaction have a pronounced effect on 
immunoassays and competitive immunometric determinations but 
not on noncompetitive immunometric determinations (11). 
Once again, this difference is due to the differences in the 
optimal reagent concentrations. In an immunoassay, the 
optimal concentration of antibody tends toward zero. In 
this situation the distribution of analyte between the free 
and bound phases is very dependent upon the equilibrium 
constant. Consequently small changes in Keq can have large 
effects on the results of the determination. In a 
noncompetitive immunometric determination, the optimal 
concentration of Ab tends towards infinity and hte large 
excess of Ab drives the immunochemical reaction towards 
completion. Thus, small changes in Keq will have a 
negligible effect on the results of the determination. 
Lanthanide Chelate Labels 
and Labelling 
Lanthanide Chelates 
Several types of labels have been proposed for the 
development of immunometric determinations with very low 
detection limits. Immunoenzymatic determinations employing 
fluorescent or radioactive substrates have been reported to 
reach detection limits of 10-17 Mand 10-18 M, respectively 
(14,15). Chemiluminescent labels can be detected at le~els 
down to at least io-18 molecules.(16). Although 
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commercially available instruments cannot reach this level, 
improvements in instrument design should make 
chemiluminescent techniques more competitive. 
Conventional fluorescent labels are detectable at very 
low levels but, unfortunately, this has been limited in 
actual application by high background noise, which is 
primarily due to light scattering and the presence of other 
f luorophores in the solution. A wide range of biological 
materials exhibit fluorescence and may be present in sample 
solutions. Conventional fluoroimmunochemical determinations 
usually have a higher detection limit than radioisotopic 
methods. If the background fluorescence can be reduced, the 
detection limit of the fluoroimmunochemical determinations 
should improve. 
The ideal fluorescent label should be stable, with high 
molar absorptivity and quantum yield in aqueous solution. 
It should also have excitation and emission wavelengths 
above those of most background materials (~ex > 360 nm and 
"em > 500 nm) and should not interfere with the antigen -
antibody binding. Some rare earth metal ions, especially, 
Eu+3 and Tb+3, form highly fluorescent chelates with organic 
ligands that fulfill many of these qualifications (17), 
including low detection limits (Nlo-14 M), long fluorescence 
lifetimes (10 to 1000 µs), large Stoke's shifts (>250 nm), 
broad excitation bands, and narrow emission lines (3). The 
long lifetimes of the metal chelates is very important, 
since the average decay time of background fluorescence is 
less than lQO ns; thus, the background fluoresence can be 
significantly reduced by selectively detecting long-lived 
fluorescence. 
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Figure 5 depicts the generally accepted view of the 
energy transfer processes involved in lanthanide chelate 
fluorescence (18). Energy is absorbed by the organic 
ligand, which is then excited from the singlet ground state 
to the first excited singlet state. Intersystem crossing 
then occurs from the singlet excited state to the triplet 
excited state, followed by intermolecular energy transfer 
between the triplet state of.the ligand and the resonance 
levels of the rare earth ion. Finally, the excited metal 
ion emits a photon; thus, the frequency of the emitted 
light is characteristic of the metal itself and independent 
of the nature of the ligand. The other charateristics of 
the fluorescence process, such as quantum efficiency, 
excitation maxima, intensity, lifetime, etc., are strongly 
dependent on the nature of the ligand and the solvents used 
(12). The ligand should be as highly absorbing as possible 
at a suitable wavelength so that the triplet state of the 
ligand is a little above the resonance line of the metal 
ion. Also, efficient intermolecular energy transfer 
requires a strong, stable bond between the metal ion and the 
ligand. 
In time-resolved fluoroimmunochemical techniques, a 
bifunctional chelating agent is used to couple the metal ion 
to the molecule to be labelled (either Ab or Ag); the 
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Energy Level Diagram of a 
Europium (III) Chelate. 
From Reference (12). 
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reagent must form a strong, stable metal chelate without 
disrupting the immunochemical reaction between the antibody 
and the antigen. The bifunctional reagents used in 
time-resolved fluoroimmunochemical determinations can be 
divided into two groups, depending on whether or not the 
final labelled complex is a strong fluorophore. Dakubu and 
coworkers (12) call them reagents of the first and second 
class, respectively. If the complex is of the second class, 
the fluorescence measurement is made after the 
immunochemical reaction by dissociating the metal ion from 
the complex into a solution containing chelating chromo-
phores that are good energy donors. Bifunctional labelling 
reagents of the first class may be used like conventional 
fluorophores, but have the added advantage of very long 
lifetimes and large Stoke's shifts. There may also be some 
excitation energy transfer from a labelled protein molecule 
to the lanthanide chelate (19). 
The use of a labelling reagent of the first class rather 
than of the second class seems to be advantageous. 
Additional reagents and an extra incubation step are 
required to get a fluorescence signal from a label of the 
second class; however, the chelates that form the most 
highly fl~orescent lanthanide complexes (P-diketones) cannot 
be used as reagents of the first class because the stability 
of these complexes is not high enough (8,20). Certain 
europium,P-diketone complexes have detection limits that are 
the same or better than the detection limit of 1251 (17). 
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These complexes can be used in an immunochemical determina-
tion designed for a labelling reagent of the second class. 
In contrast to ~-diketone complexes, polyaminopoly-
carboxylic acids form lanthanide complexes of very high 
stability (21). Most reagents of the first class are 
polyaminopolycarboxylic acids. Table I lists some labelling 
reagents of the first class used in time-resolved fluoro-
immunochemical determinations and their fluorescence 
characteristics. Because of the lower fluorescence 
intensity of the polycarboxylic acid chelates, the detection 
limits for these labelling reagents are all higher than 
desired. Most reagents of this class have been combined 
with Tb+3 ions to form the fluorescent chelate, because 
Terbium forms more stable complexes in water and doesn't 
require the addition of other compounds to reduce 
fluorescence quenching by water molecules (17). However, 
the lower.excitation wavelength may necessitate the use of 
quartz cells. 
Europium polycarboxylic acid complexes are very 
sensitive to quenching by water molecules. Recently, 
Diamandis and coworkers (22-24) reported using a europium 
polycarboxylic acid complex, 4,7-bis(chlorosulfophenyl) 
-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA) as a 
labelling reagent of the first class. BCPDA forms a 1:1 
complex with Eu+3 unless it is present in excess, in which 
case, complexes with more than one BCPDA can form. The 
chelating site consists of two carboxyl groups and two 
TABLE I 
FLUORESCENCE CHARACTERISTICS OF SOME BIFUNCTIONAL 
LABELLING REAGENTS OF THE 1st CLASS 
Reagent Metal Ion (nm) (nm) (ms) LODf Reference ex em 
eryt.hrosin - 540 690 0.26 0.11 nM 50 
transferrin Tb+3 295 545 1.25 0.11 uM 46 
pAS-DTPA a Tb+3 312 545 1.58 <0.5 nM 48,79 
diazophenyl-EDTAb Tb+3 325 550 1.01 0.3 nM 49 
aminophenyl-PPTAc Tb+3 - 545 - - 78 
BCPDA d Eu+3 337 613 0.76 10 pM 25 
W-1174 e Eu+3 355 613 0.42 - 27 
a p-aminosalicylatediethylenetriaminepentaacetic acid. 
b 1-(p-benzenediazoniumethylenediaminetetraacetic acid. 
c 2,6-bis[(N,N-dicarboxymethyl)aminomethyl]-4-[2-methoxyphenyl]pyridine tetraacetic acid. 
d 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid. 
e New compound from Wallac Organic Laboratories, not yet commercially avaliable. 
f Limit of Detection. 
IV 
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heteroaromatic nitrogens. When BCPDA is immobilized on a 
solid surface in the presence of excess Eu+3, the normal 
washing steps of an immunometric determination will not 
remove Eu+3 from the labelling reagent. A detection limit 
of 2xlo-12 M was achieved for the 1:1 complex by adding a 
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phenanthroline group to the polycarboxylic acid to get more 
effective energy transfer to the europium ion, and by 
measuring the fluorescence of the complex on a dry solid 
surface. There are, however, instrument design and 
reproducibility problems associated with measuring 
fluorescence from nonuniform solid surfaces (17). 
A new labelling reagent of the first class was used in 
two recently published homogeneous TRFIAs (27,28). The 
europium chelate (W-1174) was prepared by Wallac Organic 
Chemistry Laboratory and is not yet commercially avaliable. 
The labelling reagent has excitation and emission maxima at 
355 and 613 nm, respectively, and a fluorescence lifetime of 
428 us. The structure of the chelate was not given, but the 
chelate was reported to have a stable complexing moiety, a 
functional group with a spacer arm for conjugation 
reactions, and a light absorbing aromatic structure. The 
excitation and energy-donating properties of the aromatic 
structure are sensitive to changes in the chelate's micro-. 
environment that take place when the labelled species is 
bound in an immunochemical reaction. In the presence of 
albumin or detergents, the fluorescence of the free fraction 
of the labelled species is higher than that of the bound 
fraction. 
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All of the labelling reagents of the second class that 
have been reported in the literature are polyamine 
polycarboxylates. The chelates all contain either an 
isothiocyanate or a diazo group to facilitate attachment to 
the molecule being labelled. The most commonly-used 
labelling reagents in this class are isothio-
cyanatophenyl-EDTA and isothiocyanatophenyldiethylene-
tr iaminetetraacetate. After the immunochemical reaction, 
the metal ion in the bound phase can be dissociated from the 
chelator by lowering the pH to 2 or 3 (21). This is usually 
done with an acidic "enhancement" solution containing a 
p-diketone, "synergistic" compounds, and a nonionic 
detergent. 
Because of their rigidity and good pi-electron 
delocalization, ~-diketones (R1cocH2coR2 ) form highly 
fluorescent complexes with lanthanide ions (12). The 
fluorescence characteristics of the complexes can be changed 
by varying the nature of the functional groups in the R1 and 
R2 positions. Fluorescence intensity can be enhanced by 
using bulky substituents and good electron donors in these 
positions. The ~-diketone forms a tris chelate with the 
metal ion as show in Figure 6. The Eu+3 ion has a 
coordination number of eight (29). Six oxygen atoms are 
available for coordination from the ~-diketone. If the 
coordination is completed by filling the last two positions 
[ 1c=o ] ij-C \ 




Figure 6. Structure of a Europium (III) 
-Diketone Synergist Complex. 
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with the oxygens of water molecules, then the fluorescence 
will be severely quenched. The "synergist", a Lewis base, 
is added to the enhancement solution to reduce the 
quenching. The best of these compounds are neutral 
molecules that have a lone oxygen atom for coordination to 
the metal, combined with a bulky, saturated hydrocarbon tail 
directed away from the metal ion. Tri-n-octylphosphine 
oxide (TOPO) is the most commonly used "synergist". A 
nonionic detergent, such as Triton X-100, is also added to 
the enhancement solution to solubilize the -diketone and 
the "synergist", and to provide a more hydrophobic 
environment for the chelate. 
Fluorinated aromatic fo-diketones produce the most 
intense fluorophores with europium and samarium ions (17). 
The lifetimes of the samarium chelates are shorter than that 
of the europium chelates and their detection limit is two 
orders of magnitude higher (30). Terbium does not form 
highly fluorescent chelates with aromatic,B-diketones, 
probably because the excited state triplet levels of the 
fo-diketone are slightly lower than the emission level of 
Tb+3 (31). Fluorinated, aliphaticfi-diketones in ·acidic 
TOPO and detergent solution give good signals for both 
europium and terbium. Table II shows some ~-diketone 
complexes and their fluorescence charateristics. 
Double-label methods involving the simultaneous 
measurement of two different lanthanide ions are feasible if 






FLUORESCENCE CHARACTERISTICS OF SOME LANTHANIDE 
~-DIKETONE COMPLEXES 
Conditions Metal Ion ).. ex (nm) )... em(nm) Y (us) 
TOPO,TX-100, ~H 3.2 Eu+3 354 618 300 
TOPO,TX-100, pH 3.5 Eu+3 337 613 430 
Eu+3 340 613 430 
Sm+3 340 643 41 
TOPO,TX-100, pH 4.0 Eu+3 308 614 1020 































under the same reaction conditions. The pairs (Eu+3, Tb+3) 
and (Eu+3, sm+3) meet this requirement. In 1987 Bador et 
al. (30) suggested the use of europium and samarium in a 
double-label system. Earlier, Hemmila and coworkers (17,31) 
suggested the europium, terbium pair, and late in 1987 the 
first report of an actual double-label time-resolved 
immunofluorimetric determination was published (32). The 
limits of detection found by Hemmila and coworkers for their 
europium and terbium complexes are shown in Table II, along 
with the detection limits found by Bador et al. (30) for 
their europium and samarium comlexes. 
The Eu+3, sm+3 system has lower detection limits than 
~he Eu+3, Tb+3 system. The detection limits of both labels 
in the Eu+3,Tb+3 system are significantly higher than that 
of 125I. In the Eu+3,sm+3 system, the detection limit of 
the samarium label is an order of magnitude higher than that 
of 125I. The Eu+3,Tb+3 system also has a higher excitation 
wavelength, which would allow the use of disposable plastic 
cells or microtitration strips. The aliphatic ~-diketone 
used by Hemmila and coworkers has an excitation wavelength 
just above 300 nm~ all available disposable glass or plastic 
containers absorb light in this region. In addition, normal 
glass contains rare earth ions which have been found to emit 
strong long-lived fluorescence (31). The type of 
microtitration strips used by Hemmila et al. (32) in their 
double-label determination was not reported, but were 
probably polystyrene as this was the type used in their 
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earlier determination with terbium labels (31). The terbium 
label was found to cause a slight interference 1%) with 
the determination of the europium label due to the minor 
spectral overlap of the terbium emission at 621 nm near the 
main emission peak of europium. The overlap of the europium 
and samarium chelates (30) seems to be larger than that of 
the europium and terbium chelates but no mention was made of 
any interference. The difference in fluorescence lifetimes 
of the europium/samarium system is larger so minor spectral 
overlap may be less critical. 
Labelling 
In most immunochemical determinations, each molecule is 
labelled with just one 125I atom to avoid the possiblility 
of the radioactive tracer damaging the labelled reagent (1) 
or disrupting the antigen-antibody binding. In fluoroim-
munochemical determinations, the possibility of multi-
labelling exists as long as the immunochemical reaction is 
not disrupted. Increasing the number of fluorophores per 
labelled molecule should result in an increase in the total 
fluorescence per labelled molecule, which in turn should 
lower the detection limit. However, concentration quenching 
can result when several fluorophores are immobilized close 
together. Fluorescein, the most commonly used conventional 
fluorophore, is very susceptible to this phenomenon (4). 
Multilabelling is relatively simple in immunometric 
techniques because the antibody is a large protein. In 
immunoassays the labelled molecule may not be a large, 
easily labelled molecule; thus, several indirect 
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multilabelling techniques have also been developed. In the 
first technique, a multilabelled carrier molecule, usually a 
large protein, may be attached to the analyte or antibody. 
This method is especially good for haptens like steroids 
which have a unique or restricted number of sites at which 
labels may be attached. The second type of indirect 
labelling involves another binding system such as Protein A, 
avidin/biotin, streptavidin/biotin or a second-antibody 
(33). Protein A binds to the constant region of the heavy 
chain of IgG. Its binding constant is slightly lower than 
that of most Ab/Ag complexes. Avidin and streptavidin bind 
biotin molecules. This system has a very high equilibrium 
constant (1015 M-1). Each avidin can bind two biotin 
molecules and each streptavidin can bind one biotin. The 
second-antibody system uses another antibody directed 
against the antibody that binds the analyte. In each of 
these cases, the new binder is a large protein which can be 
multilabelled. In the avidin/biotin and streptavidin/biotin 
-
systems, antibodies are usually biotinylated; thus, avidin 
or streptavidin would be multilabelled. In another system, 
steptavidin is indirectly labelled via a thyroglobulin 
carrier molecule. As many as 160 chelating agents may be 
attached to the thyroglobulin (34). Protein A and avidin 
are universal labels in that they may be used in any system 
once they are labelled. The second-antibody technique 
requires a series of animal species-specific antibodies. 
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Lanthanide chelates are usually attached to the antigen 
or antibody with an isothiocyanate, diazo or sulfonyl 
chloride group. Isothiocyanate reacts under mildly basic 
conditions with primary and secondary amine groups. The 
diazo group reacts with free tyrosine residues and to a 
lesser extent with histidine, lysine, arginine, and 
tyrptophan residues. Sulfonyl chloride groups react 
primarily with the amine groups on proteins under relatively 
mild conditions. Attachment via the isothiocyanate or 
sulfonyl chloride groups, rather than the diazo groups, 
usually allows for more fluorophores per molecule without 
loss of immunoreactivity. For example, Hemmila et al. (17) 
found that the optimal conjugation ratio of Eu+3 labels per 
antibody molecule was 3-5 with the diazo group but up to 50 
with the isothiocyanate group in an immunofluorimetric 
determination of IgG. Diamandis and coworkers (15) reported 
the attachment of up to 20 lanthanide chelates per antibody 
with so2c1. 
There have been nine reports of indirect labelling in 
time-resolved immunochemical determinations. One was in an 
immunoassay of progesterone that used Horseradish Peroxidase 
as a carrier molecule (35). The second was a competitive 
immunometric determination of cortisol (24), which used 
multilabelled bovine serum albumin to label the anti-
cortisol antibody. The remaining papers (22,23,34,36-39) 
36 
used a biotin/streptavidin system to label antibodies in 
immunometric determinations. All of the reports of indirect 
labelling, except the immunoassay, used labelling regents of 
the first class. The lanthanide chelate labels of the first 
class do not seem to be very sensitive to concentration 
quenching; in fact, fluorescence intensity enhancement has 
been reported with the BCPDA chelates. When thyroglobulin 
was multilabelled and complexed with Eu+3, a six-fold 
fluorescence enhancement was observed (34). Concentration 
quenching is not a consideration with labelling reagents of 
the second class because the fluorescent chelate is not 
formed until the lanthanide ion is dissociated from the 
labelled molecule. Therefore, multilabelling sould be 
advantageous for labels of the second class, also. 
Instrumentation 
The achievable detection limit in fluoroimmunochemical 
determinations is mainly limited by the background 
fluorescence and, thus, a technique that could distinguish 
the fluorescence of the label from the background would 
significantly improve the limit of detection. Most 
background fluorescence has a decay time in the ten 
nanosecond range. As noted in the last section, lanthanide 
metal chelates have lifetimes in the microsecond to 
millisecond range. In conventional fluorescence, the 
background is reduced primarily by careful selection of 
excitation and emission wavelengths with filters or 
monochromators; however, these techniques cannot entirely 
eliminate the background fluorescence. 
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When a fluorophore is excited by pulsed light, 
fluorescence is emitted following each pulse with an 
intensity which decays exponentially at a rate governed by 
the speed of the electronic transitions involved (40). As 
shown in Figure 7 , an electronically-gated detection system 
can be used to accumulate photons over any selected time 
interval after the excitation pulse and background signals 
have decayed to zero. This system may be used to measure 
the signal from a long-lived f luorophore by permitting the 
short-lived fluorescence to decay to zero before starting 
photon measurement. Conventional fluorphores cannot be used 
in this technique because their fluorescence lifetimes are 
too short. Table III shows the lifetimes of some conven-
tional fluorophores used as labels in immunochemical 
determinations. Even if N-(3-pyrene)-maleimide, with a 
lifetime of 100 ns, is used, a significant contribution from 
the background would be expected if a substantial portion of 
the specific fluorescence from the fluorophore was within 
the measurement interval of the detection system (8). The 
fluorescence of the lanthanide chelates has a much longer 
lifetime and therefore all the nonspecific background will 
have decayed before the majority of the chelate's 
fluorescence has decayed. The lanthanides also have a large 
Stoke's shift (>200 nm). These two characteristics have 










Discrimination of fluorescence signal from fluorescence of 
shorter lifetime by selection of photon cmmting time. 
Figure 7. Schematic Representation of Time-Gated 
Detection. Showing Discrimination ·of 
fluoresence signal, 0 , from fluor-
escence of shorter lifetime, @) , by 




FLUORESCENCE LIFETIMES OF SOME CONVENTIONAL 
FLUOROPHORES 
Fluorophore Lifetime 
Fluorescein isothiocyanate (FITC) 4.5 ns 
Rhoda mine B isothiocyanate (RITC) 3.0 ns 
Dansyl Chloride 14.0 ns 
Fluorescamine 7.0 ns 









inexpensive pulsed-light, time-resolving fluorometers which 
are capable of yielding high signal-to-noise ratios. 
Soini and Kojola (41) have developed a manually 
operated fluorometer for time-resolved fluoroimmunochemical 
determinations with lanthanide chelates as labels. A block 
diagram of their instrument is shown in Figure 8. The 
source is a xenon flashtube with a flash duration of 0.5 µs. 
Because the intensity of the flashes was not very 
reproducible, an integrator for a semiconductor photodiode 
was used as a stabilizer for the flashlamp. The detector is 
a photomultiplier tube operated in the single-photon mode. 
The pulse generater activates both the flashlamp and the 
timing of the emission counter. Interference band-pass 
filters mounted inside the sample compartment are used for 
excitation and emission wavelength selection. This design 
is also the basis for the commercially available 
computer-operated 1230 Arcus time-resolved fluorometer from 
LKB-Wallac. The intensity of the excitation beam in this 
type of instrument could possibly be increased by using a 
more intense source, such as.a_ pulsed laser. 
Another time-resolved fluorometer, shown in Figure 9, 
was developed in 1985 by Kuo and coworkers (42) specifically 
for use with terbium labels. They used a helium-cadmium 
laser with a continuous output at 325 nm for the excitation 
source. The excitation beam was pulsed by periodically 
interrupting the beam with a variable frequency chopper, and 












Block Diagram of the Time-Resolved 
Fluorometer Developed by Soini and 
Kojola from Reference (41). 
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M, mirror; F, filter; PMT, photomultiplier tube; and 
A.D., analog-to-digital converter. 
Figure 9. Schematic Diagram of the Time-Resolved 
Fluororneter Built by Kuo and Coworkers. 
From Reference (42). 
42. 
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an interference filter. A fast photodiode was used to 
monitor the beam and to trigger a pulse generator to open 
the gate of the photon counter after a set period. The 
chopper and the optical system are designed to block the PMT 
while the sample is exposed to the laser beam, to prevent 
PMT saturation by stray light or short-lived fluorescence. 
An oscilloscope was used to monitor the photodiode and PMT 
output in order to optimize the timing sequence and 
duration. The use of a laser and chopper eliminates the 
need for a complicated system, such as was used by Soni and 
Kojola to maintain the reproducibility of the xenon flash-
tube. The main disadvantage of the laser system is the lack 
of wavelength selection. This particular instrument can 
only be used for compounds that absorb very near 325 nm. 
In 1986, Dechaud et al. (43) reported the developement 
of a simple time-resolved fluorometer with a pulsed laser as 
the source. A block diagram of the instrument is shown in 
Figure 10. The laser emits at 337.1 nm and wavelength 
selection is accomplished by interference and sharp-cut 
filters; the emission filters could be replaced by a 
monochromator for spectroscopic studies. The detector is a 
PMT operated in the photon-counting mode with processing of 
the signal by a fast pre-amplifier and a discriminator. The 
start of the timing sequence is triggered by the control 
unit of the laser. The high output of the laser is very 
near the wavelength of maximum absorbance for the 
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source may very well be the reason for the lower detection 
limit of the europium ~-naphthoyltrifluoroacetone complex 
(30) using this instrument (see Table II). The pulsed laser 
in this instrument has very stable pulses, which eliminates 
the need for a chopper. On the other hand, pulsed lasers 
are larger and more expensive than continuous wave lasers, 
which may limit their application for clinical use. 
A fourth type of time-resolved fluorometer was used by 
Diamandis and coworkers (22-24,44) to detect fluorescence 
from dry, solid surfaces. The instrument was a CyberFluor 
615 gated fluorometer, which uses a pulsed nitrogen laser 
that laser has a pulse duration of 3-4 ns and a repetition 
rate of 20 pulses per second. A diagram of the CyberFluor 
615 optical system is shown in Figure 11. This instrument 




The first papers reporting the use of time-resolved 
fluoroimmunometric determinations were published in 1982. 
Since then, determinations of many species of clinical 
interest using time-resolved fluoroimmunochemical techniques 
have been published. The techniques fall into two major 
categories, immunoassays and immunometric determinations, 
depending upon whether the label is attached to the antigen 
or the antibody. The labelled antibody category is further 
L2 Collimating Lens 
F 2 Liquid Filter 
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F3 lnter1erence Filter 
PM1 Photomultiplier 
Figure 11. The Optical System of the CyberFluor 615 Time-
Resolved Fluorometer. From Reference (44). 
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divided into competitive and noncompetitive techniques; the 
bulk of the determinations that have been reported fall into 
the noncompetitive labelled antibody category. Table IV 
lists the determinations that have been reported in each 
category according to the type of species determined and the 
labelling reagent employed. 
As reported in a previous section, noncompetitive 
immunometric determinations are theoretically capable of 
reaching lower limits of detection than either immunoassays 
or competitive immunometric determinations. The detection 
limit, ·working range, coefficient of variation, and analysis 
times of the competitive time-resolved fluoroimmunochemical 
determinations and the noncompetitive time-resolved 
immunofluorometric determinations are reported in Table V 
and Table VI, respectively. These parameters are very 
similar for competitive immunometric determinations and 
immunoassays, which are both competitive techniques. 
Most haptens can not be determined using the "sandwich" 
immunometric technique because they are too small to have 
two well-separated determinants. All of the competitive 
determinations that have been published are either for 
haptens or a model analyte. The first time-resolved 
immunochemical determinations were reported by a group of 
scientists at the Wallac Biochemical Laboratory. They 
originally focused on the time-resolved approach to 
f luoroimmunochemical determinations as a means of reaching 
lower detection limits than were possible with 
TABLE IV 
ANALYTES DETERMINED BY TIME-RESOLVED 
IMMUNOCHEMICAL METHODS 
Analyte Type a Labelling Reagent Class b 
Model Analytes 
IgG TRFIA diazophenyl-EDTA-Tb 1 
HSA TRFIA pAS-DTPA-Tb 1 
Drugs 
Gentamicin TRFlA Transferrin-Tb2 1 
CBZ TRPhIA erythrosin 1 
D1goxin cTRlFMA pSCN-DTTA-Eu 2 
Bases 
5-MedC'yd TRFIA SCN-phenyl-EDTA-Eu 2 
5-MedCyd cTRlFMA SCN-phenyl-EDTA-Eu 2 
Steroid Hormones 
Progesterone TRFlA DTP A-Eu 2 
E-3-G TRFlA W-1174 1 
Testosterone cTRlFMA SCN-EDTA-Eu 2 
Cortisol cTRlFMA SCN-phenyl-EDTA-Eu 2 
Cortisol cTRIFMA BSA-BCPDA-Eu 1 
Cortisol cTRlFMA streptavidin-BCPDA-Eu 1 
Glycoprotein Hormones 
Thyrotropin ncTRlFMA SCN-phenyl-EDTA-Eu 2 
Thyrotropin ncTRIFMA SA-TG-BCPDA-Eu 1 
hCG ncTRlFMA diazophenyl-EDTA-Eu 2 
free hCG ncTRIFMA SCN-phenyl-EDTA-Eu 2 
hCG ncTRlFMA streptavidin-BCPDA-Eu 1 
Lutropin ncTRlFMA SCN-EDTA-Eu 2 
Lutropin ncTRIFMA SCN-DTTA-Eu 2 
Lutropin ncTRIFMA streptavidin-BCPDA-Eu 1 
Follitropin ncTRlFMA SCN-DTTA-Tb 2 
Follitropin ncTRIMFA DTP A-Eu 2 
Follitropin ncTRIFMA DTP A-Sm 2 
Polypeptide Hormones 
ACTH ncTRIFMA Scn-phenyl-EDTA-Eu 2 
Prolactin ncTRIFMA DTP A-Eu 2 
Thyroxin TRFIA W-1174 1 
Insulin ncTRIFMA SCN-phenyl-DTTA-Eu 2 































TABLE IV (Continued) 
Analyte Type a Label ling Reagent Classb Reference 
Viral Analytes 
HBsAg ncTRIFMA diazophenyl-EDTA-Eu 2 69 
Rubel la Ab ncTRIFMA diiazophenyl-EDTA-Eu 2 68 
Rotavirus ncTRIFMA diazophenyl-EDTA-Eu 2 55 
Adenovirus ncTRIFMA diazophenyl-EDTA-Eu 2 55 
RSV ncTRIFMA diazophenyl-EDTA-Eu 2 55 
I nfl uenzavirus ncTRIFMA diazophenyl-EDTA-Eu 2 55 
p-infl uenzavirus ncTRIFMA diazophenyl-EDTA-Eu 2 55 
Misc. Proteins 
a-fetoprotein ncTRIFMA SCN-phenyl-EDTA-Eu 2 70 
a-fetoprotein ncTRIFMA streptavidin-BCPDA-Eu 1 23 
a-fetoprotein ncTRIFMA SA-TG-BCPDA-Eu 1 34 
Phospholipase A2 ncTRIFMA SCN-phenyl-EDTA-Eu 1 74 
CA 125 ncTRlFMA SCN-phenyl-DTTA-Eu 2 72 
SHBG ncTRIFMA SCN-phenyl-DTTA-Eu 2 71, 76 
34 kDa SmBP ncTRIFMA SCN-phenyl-EDTA-Eu 2 73 
a-interferon ncTRIFMA 2 75 
ferritin ncTRIFMA streptavidin-BCPDA-Eu 1 39 
PPS ncTRlFMA SCN-phenyl-EDTA-Eu 2 77 
CEA ncTRIFMA SCN-PPTA-Tb 1,2 78 
CEA ncTRIFMA p-nitrophenoxy-DTPA-Eu 2 78 
a 
b 
Type of determination, cTRIFMA is competitive, ncTRIFMA is noncompetitive. 
Class of Labelling Reagent. 
Analytes 
IgG - lmmunoglobulin G 
RSA - Human Serum Albumin 
CBZ - Carbemazepine 
5-MedCyd - 5-methyl-2'-deoxycytidine 
E-3-G - Estrone-3-glucuronide 
hCG - Choriogonadotropin 
ACTH - Corticotropin 









- Hepatitis B surface antigen 
- Respiratory syncytial virus 
- Sex-hormone binding protein 
- Somatomedin binding protein 
- Placental Protein 5 
- Carcinoembryonic antigen 
- Epidermal growth factor 
For labelling reagents of the first class see Table I. 
Labelling Reagents 
SCN - isothiocyanate 
EDTA ethylenediaminetetraacetic acid 
DTPA diethylenetriaminepentaacetic acid 




radioimmunochemical methods. Their work is the basis of a 
commercially available immunochemical system from LKB-Wallac 
called Dissociation-Enhanced Lanthanide Fluoroimmunoassay 
(DELFIA) . The DELFIA system uses a polyaminepolycarboxylate 
labelling reagent of the second class and an enhancement 
solution, added after the immunochemical reaction, con-
taining ~-naphthoyltrifluoroacetone (f.>-NTA), TOPO, and 
Triton X-100 at approximately pH 3. Because of the step 
involving a highly fluorescent secondary chelate, the DELFIA 
system is susceptable to contamination from free europium in 
the environment. Homogeneous determinations are also not 
possible with this system. Most of the immunometric 
determinations that have been reported use this system. 
Recently, a group of scientists, at CyberFluor Inc., 
has developed a new lanthanide labelling reagent of the 
first class, whose a detection limit which seems to be only 
slightly higher than the europium chelate used by 
LKB-Wallac. The fluorescence of the bound fraction of the 
labelled species is measured on the dry solid phase after 
the separation step. In all instances, this label has been 
-
used with some type of indirect labelling technique, usually 
involving biotin and streptavidin, to increase the number of 
fluorophores per labelled molecule. This is almost the only 
label of the first class that has been used in a 
time-resolved immunometric determination. Conversely, all 
but two of the time-resolved immunoassays reported have used 
a label of the first class. Because most of the 
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immunometric determinations have used the DELFIA system, the 
determinations of any particular type of analyte are very 
similar. Most of the pertinent information on these 
determinations is presented in Tables V and VI. The general 
characteristics of the determination of each type of analyte 
will be reviewed and any new or unique approaches are 
discussed in the following sections of this chapter. 
Labelled-Antigen Methods 
All immunoassys are competitive techniques. In general, 
time-resolved fluoroimmunoassays (TRFIA) have higher 
detection limits and shorter working ranges but are less 
susceptible to cross-reactants and have shorter analysis 
times than noncompetitive time-resolved immunofluorometric 
assays (TRIFMA) • Immobilization of the antibody makes the 
separation step simpler and more efficient if it is needed. 
Judging by the analysis times in Table V, all TRFIAs seem to 
be nonequilibrium techniques. The first TRFIA was reported 
in 1984 (45). Between 1984 and November of 1988 only four 
mo~e TRFIAs were published and, as stated above, two of 
these were for model analytes (42,46). No subsequent 
applications of either of these two systems have been 
reported. Since November of 1988, three more TRFIAs have 
been reported, two of which were homgeneous systems. The 
lowest TRFIA detection limit was for the determination of 
progesterone (35), which is also the only reported use of 
the DELFIA system in an immunoassay. A carrier molecule was 
TABLE V 
COMPARISON OF THE WORKING RANGES, PRECISION, ANALYSIS TIMES AND 
LABELLING METHODS OF TRFIAs AND COMPETITIVE TRIFMAs 

















NR Not reported. 
NR 
25 - 50 g/l 
50 - 2000 nM 
0.8 - 300 UM 
0.6 - 200 nM 
10 - 458 nM 
50 - 300 nM 
18 - 12500 nM 
0.3 - 10 nM 
3 - 2000 nM 
30 - 1000 nM 
28 - 1300 nM 
0.3 - 5 nM 
0.5 - 25000 nM 
NR NR NR 
20 5% 1.0 hr 
NR 5% 1.5 hr 
12 <10% 0.5 hr 
10 <4% 3.5 hr 
24 3% 2.5 hr 
12 <5% 1.0 hr 
8 <5% 0.5 hr 
9 <10% 2.0 hr 
12 <8% 2.5 hr 
10 <10% 1.5 hr 
12 11% 1.5 hr 
10 <7% 1.0 hr 
NR 11% 2.0 hr 
a Number of replicates used to calculate the RSD. 
b Relative Standard Deviation, in percent. 
c Analysis Time. 
d Human Serum Albumin. 




















used to increase the Eu/Ag ratio to five and the antibody 
was immobilized on the polystyrene sample tubes. The main 
reason this TRFlA has the lowest detection limit is that it 
used the label with the lowest detection limit. The 
detection limit of the label in this TRFIA is several orders 
of magnitude lower than that of any of the other labels used 
for TRFIAs. 
The two new homogeneous TRFIAs, one for the 
determination of thyroxin (27) and the other for the 
determination of estrone-3-glucuronide (28), used a new 
labelling reagent of the first class (W-1174). They are the 
first homogeneous time-resolved fluoroimmunochemical 
determinations to be published. Both are based upon 
quenching of the fluorescence of labelled antigen when it is 
antibody-bound. No lifetime selectivity between Ag* and 
Ag*-Ab is possible with the TRFIAs; the time discrimination 
is still just used to eliminate background fluorescence. In 
the TRFIA of thyroxin N90% of the fluorescence was quenched 
by anti-thyroxin antibodies. An amount of Ab large enough 
to bind most of the Ag* was used in order to ~educe the 
incubation time. Both determinations had short analysis 
times and good reproducibility. The developement of 
homogeneous TRFIAs is an important step. It should make 
TRFIAs a viable alternative to the popular TDX fluorescence 
polarization immunoassay system in the area of therapuetic 
drug monitoring. 
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The TRFIA of 5-methyl-2 1 -deoxycytidine is unique in 
that it used polylysine as a bridge between the europium 
chelate and the anigen (47). This base is the only modified 
or minor base in mammalian DNA, and is thought to be a 
regulator of eucaryotic gene transcription. The tracer was 
labelled 5-methylcytidine, and an immobilized second 
antibody directed at IgG was used to separate the bound 
fraction from the free fraction. The TRFIA had a working 
range of three orders of magnitude, which is very wide for 
an immunoassay. 
One of the most interesting time-resolved 
determinations is not technically a TRFIA since the label is 
phosphorescent rather than fluorescent, but the technique is 
very similar (48). The label is erythrosin, a tetraiodo-
fluorescein derivative, the phosphorescence of which was 
measured at room temperature in aqueous solution after 
chemical removal of oxygen with sodium sulfite. The phos-
phorescence of the label is quenched by about 80% upon 
antibody binding, so that no separation step is needed. 
Although this immunoassay doesn't have a very low detection 
limit {N8x10-7 M) it is low enough for some applications 
such as therapeutic drug monitoring. Sidki et al. (48) have 
found that the phosphorescence of this label on a variety of 
haptens is quenched by all of the antisera they studied. 
Competitive Labelled-Antibody Methods 
All six competitive TRIFMAs that have been reported 
involve the use of a solid phase antigen along with the 
labelled antibody. Competitive TRIFMAs have similar 
detection limits, working ranges, precision, and analysis 
times to TRFIAs. Like TRFIAs, the competitive TRIFMAs are 
nonequilibrium methods for the determination of haptens. 
The determinations of digoxin, testosterone, 5-methyl-
2 '-deoxycytidine and one of the cortisol determinations 
(49-52) used the DELFIA system~ The other two cortisol 
determinations (24,36) employed indirect labelling with 
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BCPDA-Eu and solid phase detection (the CyberFluor system). 
Two different types of indirect labelling were reported 
for the CyberFluor system. The first involved using a large 
carrier molecule (BSA) labelled with up to 40 BCPDA 
molecules (24). The second involved the use of biotinylated 
antibodies and streptavidin labelled with 15 BCPDA 
molecules (36). Each biotin binds one streptavidin, while 
the antibody may have up to 16 biotin groups bound to it. 
This method has been proposed by CyberFluor as a universal 
detection system. A schematic depiction of the process is 
shown in Figure 12a. 
The digoxin TRIFMA has a narrow working range but the 
therapeutic range of this drug is only 1.0 - 2.0 nM, with 
toxcicity starting at doses above 3 nM. The steroid TRIFMAs 
also cover the normal serum values of these compounds. The 









- Ee . Eu 
~
\ 's: 







LI ! _ 
+O+ri-i 
8 B 
An11ger. 81ot 1nyJa1ed 
ant1booy 
Add s!repta111d1n l.ibelled 
with Eurof1µ01 S. contc:1in1ng 
excess Eu·'· 
' 8 8 
I I : 
f--<QLL · 
I~·
I B B 
Add streptav101n ianeiled 
w:n-. Euro11uor-S. cor.~a1n1ng 
excess Eu:• ... 
56 
B = biotin. S = streptavidin. The fluorescence of the 
final product is measured on the dry solid phase. 
Figure 12. Schematic 
Systems 
Anigens 
Depiction of the CyberFluor 
for Haptens (a) and Larger 
(b). From Reference (44). 
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lower detection limit than either of the cortisol deter-
minations using the CyberFluor systems, but the analysis 
time is also longer - approximately 2.5 hours versus about 
1.5 hours. All of these determinations showed at least fair 
correlation with their corresponding RIAs, with correlation 
coefficients (r) ranging from 0.93 for DELFIA cortisol to 
0.98 for the other cortisol determinations and the testos-
terone TRIFMA. Most competitive immunochemical techniques 
use polyclonal antibodies because of their higher binding 
strength, but in the cortisol determination with indirect 
labelling better results were produced with a monoclonal 
antibody. Perhaps the polyclonal antibody was partially 
directed against the carrier molecule and the bridging 
group. 
Noncompetitive Labelled Antibody 
Methods 
All of the noncompetitive TRIFMAs use a solid-phase 
antibody and a free labelled antibody. At least one of the 
antibodies used in these methods, if not both, is usually 
monoclonal. The analyte must have at least two antigenic 
determinants spaced far enough apart to allow two antibodies 
to bind simultaneously. The analysis can be accomplished in 
one or two incubation steps. One-step noncompetitive 
determinations frequently suffer from a "high dose hook 
effect", in which the fluorescence signal reaches a maximum 
and then decreases as the analyte concentration increases. 
TABLE VI 
COMPARISON OF THE WORKING RANGES, PRECISION, 
LABELLING METHODS OF NONCOMPETITIVE 
Species I of Working Rang-e la RS Db Time c 
Steps (hrl 
Glycoprotein Hormones 
Thyrotropin 1 O.OJ - J24 mIU/l 12 <St 2.0 
Thyrotropin 1 O.OJ - 100 mIU/l 12 <10\ 5.0 
hCG 1 0.1 - 135 IU/l 10 <10\ 2.0 
hCG 2 O. 7 - J50 IU/l 10 <10\ 4.0 
hC9 1 1.0 - 500 IU/l 15 <10\ J.5 
hCG 2 1. 5 - 500 IU/l 15 <7' 4.5 
hCG 2 0.13 - 5000 IU/l 12 <10\ 4.5 
ti:ee -hCG 2 1.0 - 200000 ng/l 12 <10\ 4.5 
l.utcopin 2 0.04 - 125 IU/l NR <8' J.5 
Lutropin 1 0.5 - 240 IU/l 15 <10\ 2.5 
Lutropin 2 I· - 250 IU/l NR 10\ 0.5 
l,utropi n 2 0.1 - 250 IU/l 12 <10\ J.5 
f'o 11 itropin • 2 4 - 250 IU/l 12 <15\ J.5 
Follitropin 1 1.2 - 135 IU/l 12 <IOl 4.0 
Follitropin 1 10 - 135IU/l 12 <15\ 4.0 
Polypeptide Hormones 
ACTH 2 25 -1000 ng/l 10 <10\ 6.0 
Prolactin l 1 - 100 mg/I 10 <6l 4.0 
Insulin l 2.4 - 2400 mlU/l 12 <10\ J.O 
Insulin 2 2.4 - 2400 mlU/l 12 <10\ 4.0 
EGF 2 2.5 - 5000 ng/l 8 <lOl 4.0 
Viral Analytes 
llBsA9 l NR NR NR J.O 





















































TABLE VI (Continued) 
Species I of 
Steps 









































1 - 10 ng/ml 
l - 100 n9/ml 
1 - 1000 n9/ml 
1 - 1000 n9/ml 






8pM - 200 nM 10 
1.5 - 7200 U/ml 5 
0.25 - 250 u9/l 12 
0.02 - lOOu 9/l 12 
0.1 - 1000 IU/ml 12 
0.2 - 1000 IU/ml 12 
0.1 - 1030 IU/ml 21 
5.0 - 500 ng/ml NR 
1.0 - 500 n9/ml NR 
0.2 - 500 n9/ml NR 
0.020 - 100 nH NR 
1.) - 1100 UH 12 
0.05 - 1000 ug/l 20 
1.0 - 400 ng/ml 5 
1.5 - NR n9/ml 5 



























a Number of replicates used to calculate the RSD. 
b Relative Standard Deviation. 
c Analysis time. 
















































A typical two-step calibration curve and a one-step 
calibration curve showing the hook effect are shown in 
Figure 13. If a one-step TRIFMA suffers from the hook 
effect, the samples need to be run at more than one dilution 
in order to determine the analyte concentration. If no hook 
effect occurs, then the one-step method is advantageous 
because the second incubation step can be eliminated and the 
analysis time shortened. Two-step methods usually have a 
wider working range but frequently show higher limits of 
detection than one-step methods. Most noncompetitive 
sandwich methods use monoclonal antibodies to reduce 
nonspecific binding even though they generally have lower 
binding constants than polyclonal antibodies. High binding 
constants are not as important in noncompetitive 
immunometric determinations because they are reagent-excess 
techniques. 
It is difficult to compare time-resolved fluoroimmuno-
chernical determinations to other types of labelled 
immunochemical determinations strictly on the basis of the 
type of label.used because the particular antibody prepara-
tions used are so critical to the outcome. Fortunately, 
some reports of irnrnunornetric determinations using different 
labels but the same antibodies have been published 
(46,53-55). For the purposes of this review, the noncom-
petitive TRIFMAs have been divided into groups according to 
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Figure 13. 
R'j/ml 
Typical Immunometric Calibration Curves With (a), and 
Without (b), a Hook Effect. From Reference (56). 
hormones, polypeptide hormones, viruses and their related 
antigens and antibodies, and other miscellaneous proteins. 
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Determination of Glycoprotein Hormones. The glyco-
protein hormones, human choriogonadotropin (hCG), 
thyrotropin (TSH), lutropin (LH), and follitropin (FSH) have 
all been determined by noncompetitive TRIFMA. These 
hormones are all composed of two subunits. Theo<. subunits 
of each hormone are almost identical, while the p subunits 
are similar but differ somewhat in their amino acid 
sequences. Typically, a monoclonal antibody directed 
against either the whole hormone or one of the subunits is 
used as the solid-phase capture antibody. Another mono-
clonal antibody directed against the other subunit is 
labelled with the lanthanide chelate. The majority of 
papers discussed in this section are determinations of hCG 
and TSH and these methods are therefore discussed in greater 
detail. 
Human choriogonadotropin (hCG) is primarily determined 
for early detection and monitoring of pregnancy and 
pregnancy-related disorders (22). The first TRIFMA of hCG 
was reported in 1983 by Pettersson et. al (56). It used the 
DELFIA system. Purified anti-hCG was immobilized on the 
surface of microtiter strip wells. Purified anti-LH was 
labelled with diazophenyl-EDTA-Eu. Both one- and two-step 
procedures were developed. The one-step procedure showed a 
high dose hook effect. The two-step method has a wide 
working range, which is beneficial since the normal range of 
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hCG values is also quite wide. Stenman and coworkers (57) 
developed a very rapid (20 minute) variation of this deter-
mination, as a rapid pregnancy test, with a working range of 
1.7 - 300 IU/l. (An international unit (IU) is a quantity 
of a biological substance, in this case a hormone, that 
produces a specific internationally accepted biological 
effect.) An immunoradiometric determination (IRMA) was 
developed using the same antibodies and standards as the 
TRIFMA of hCG (53). Each labelled antibody had approx-
imately five europium chelates or two 125I atoms attached to 
it. The TRIFMA had a slightly lower detection limit than 
the IRMA (0.2 IU/l vs. 0.4 IU/l). Radiolabelled antibody 
with a higher 125I-to~antibody ratio was also studied, and 
was found to have a lower immunoreactivity and higher 
detection limit. The 125I-labelled antibody lost 50% of its 
potency in just four weeks while the europium labelled 
antibody was found to be stable for at least one year. The 
125I-labelled antibody showed greater instability than is 
normal for a radioactive immunoreagent because the 125I 
level was 10-100 times greater than normal and thus, the 
damage to the labelled reagent was also greater. 
The DELFIA system was also used to determine the 
concentration of the free ~subunit (~hCG) of hCG as well as 
the intact hCG (58). Choriocarcinoma patients with a 
therapy resistant disease have increased levels of ~hCG. A 
monoclonal Ab reacting with both free ~hCG and hCG was used 
as the solid-phase capture Ab. For the determination of hCG 
an antibody directed against the ~subunit of hCG was 
labelled, and for the determination of ~hCG, an antibody 
that reacted only with the free ~ subunit was labelled. 
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This antibody probably binds a site covered by the ol. subunit 
in intact hCG. Both determinations were two step proce-
dures. The detection limit for the hCG determination was 
similar to that previously reported using the DELFIA 
sysytem. The working range was at least ari order of magni-
tude larger than any other TRIFMA for hCG. The determin-
ation of ~hCG had a smaller working range but otherwise was 
similar to the hCG determination. The results were verified 
by first separating ~hCG and intact hCG in a sample using 
hydrophobic-interaction HPLC and then running the TRIFMAs. 
No interference of hCG in the determination of ~hCG was seen 
at hCG concentrations below 1800 IU/l. Some cross-reaction 
(about 0.6%) did occur at higher concentrations, and the 
degree of cross-reaction increased with increasing 
incubation times. 
In 1987, Khosravi and Diamandis (22) reported a new 
type of TRIFMA for hCG. The second antibody was labelled 
with biotin instead of a europium chelate. Streptavidin was 
multilabelled with BCPDA-Eu. The fluorescence of the 
resulting complex, Ab1 -hCG-Ab2-biotin-streptavidin-
BCPDA-Eu, was measured directly on the dried solid-phase by 
excitation with a nitrogen laser. Once again, both one- and 
two-step procedures were developed and the one-step proce-
dure again showed a hook effect. The detection limit of 
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this hCG determination was slightly higher than that found 
in the DELFIA system of Pettersson et. al (56), although the 
analysis times and imprecision were similar. The DELFIA hCG 
determination also showed good correlation (r = 0.99) with 
this method. 
The measurement of TSH in serum is one of the essential 
tests of thyroid function (59). The lower limit of normal 
TSH values is about 0.4 mIU/l, while hyperthyroid levels are 
less than 0.1 rnIU/l (60). Radioirnrnunoassays cannot distin-
guish between these two concentrations. A one-step TRIFMA 
of TSH was reported by Lovgren and coworkers (61) in 1984. 
They reported a sufficiently low detection limit to detect 
hyperthyroidism, and a wide working range, as shown in Table 
6. The commercial DELFIA kit developed from this system has 
been evaluated by several groups (59,60,62-64). The evalu-
ations were generally favorable; reporting low detection 
limits, good precision and good calibration. Lawson et. al 
(62), however, found the TRIFMA more expensive to perform 
than the standard free thyroxin and total thyroxin deter-
minations, with only marginally better detection limits. 
TSH has also been determined using the CyberFluor 
TRIFMA system (37). A schematic representation of their 
basic imrnunometric system using indirect labelling with the 
streptavidin/biotin reaction is shown in Figure 12b. The 
determination of TSH uses a modification of this approach, 
in which streptavidin is indirectly labelled using 
thyroglobulin as a carrier molecule. Up to 160 BCPDA 
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molecules could be attached to each thyroglobulin. The 
detection limit was the same as in the DELFIA system; 
however, the working range was shorter and the analysis time 
was doubled. 
The determination of lutropin (LH) and follitropin 
(FSH) values is often needed when the pathological 
abnormalities of male and female reproductive systems are 
investigated. The normal ranges of LH and FSR are 1 - 100 
IU/l and 4 - 250 IU/l, respectively. A two-step TRIFMA of 
LR using the DELFIA system was reported by Lovgren and 
coworkers (61). The method had a good working range, 
detection limit and precision, but showed high cross-
reactivity with hCG. Stenman et. al (65) developed a rapid 
(30 minute) version of this TRIFMA. No mention was made of 
the previously reported cross-reaction but the same 
antibodies were apparently used. 
A TRIFMA for LH using the CyberFluor system with a 
thyroglobulin carrier molecule was also reported (38). Two 
variations of the TRIFMA were given. One used longer 
incubation times (2 hours) and had a lower detection limit 
(0.5 IU/l). The other, more rapid determination, used 
shorter incubation times and had a higher detection limit 
(1.0 IU/l), but could be preformed in less than one hour. 
The working ranges and precisions were similar to the other 
determinations of LR. Some cross-reaction (5%) with hCG was 
reported and thus this TRIFMA is not recommended for samples 
from pregnant patients or new mothers. There was good 
correlation (r :N 0.96) of the TRIFMA with DELFIA and IRMA 
kits for LH determinations. 
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The first FSH TRIFMA was reported in 1987 by Bader et. 
al (30). They actually developed two different deter-
minations, one with a europium label and another with a 
samarium label. The samarium-labelled TRIFMA had a ten-fold 
higher detection limit than the europium-labelled method and 
its coefficient of variation increased rapidly for concen-
trations below 10 IU/l. Double-label TRIFMA methods for LH 
and FSH (32) were also reported in 1987. In this approach, 
purified anti-LH monoclonal antibody was labelled with a 
europium chelate and purified anti-FSH monoclonal antibody 
was labelled with a terbium chelate. The enhancement 
solution contained PTA instead of ~-NTA for reasons 
discussed earlier. The two-step, double-label TRIFMA showed 
low cross-reactivity, but higher sample volumes and concen-
trations of labelled antibody had to be used to compensate 
for the higher detection limits of these fluorophores (see 
Table II). The detection limits of the determination were 
still higher than the single-label DELFIA kits but lower 
than commercial, double-label RIA kits (32). 
Determinations of Polypeptide Hormones. The 
polypeptide hormones prolactin (LTH) , corticotropin (ACTH) , 
insulin, and human epidermal growth factor (hEGF) have all 
been determined by noncompetitive DELFIA-type TRIFMAs 
(43,54,66,67). The techniques, analysis times, and 
imprecisions are similar for all of the determinations. The 
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determinations of LTH and ACTH were both compared to IRMAs 
using the same antibodies and standards. The determination 
of LTH (43) easily covered the whole range of normal values 
(2 - 22 mg/l) and was well correlated (r = 0.98) to the 
corresponding IRMA over the entire normal and pathological 
concentration range. The determinations of ACTH (54) by 
TRIFMA and IRMA showed similar working ranges and detection 
limits, although the analysis time of the TRIFMA was 
considerably shorter than the 23 hours required for the 
IRMA. The imprecision of the TRIFMA was higher than that of 
the IRMA but still less than 10%. 
Toivonen and coworkers (66), in their determination of 
human serum insulin, noted that the use of EDTA as an 
anticoagulant in plasma samples interfered with the one-step 
TRIFMA but not with the two-step procedure. EDTA will more 
than likely interfere with all of the competitive time-
resolved fluoroimmunochemical determinations and one-step 
noncompetitive TRIFMAs using a DELFIA type system. 
Determination of Antiviral Antibodies, Viral Antigens, 
and Viruses. The first reported TRIFMAs were for the 
determination of Rubella antibodies (68) and hepatitis B 
surface antigen (69). Shortly thereafter, the deter-
minations of rotavirus, adenovirus, respiratory syncytial 
virus (RSV), inf luenzavirus types A and B, and parainflu-
enzavirus types 1, 2, and 3 were reported (55). The TRIFMA 
for Rubella virus is a noncompetitive technique even though 
it uses solid-phase antigen because the analyte is an 
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antibody. In this determination, the Rubella virus is 
immobilized on polystyrene beads and anti-human IgG is 
labelled with a europium chelate. The immobilized virus is 
used to capture the Rubella antibodies in the sample. After 
incubation and washing steps, the labelled second antibody 
is added. No detection limit was reported since this 
qualitative TRIFMA just uses a cutoff between positive and 
negative samples. 
Hepatitis B surface antigen (HBsAg) is the most common 
immunological marker of hepatitis B virus infections (69). 
A high .dose hook effect was noted in the one-step TRIFMA of 
HBsAg. The detection limit, reported as twice the signal 
level of the blank, was ~o.s mg/l. The determination of 
viruses in stool and nasopharyngeal secretions by Halonen 
et. al (55) used the indirect labelling method shown in 
Figure 14. These determinations were compared to IRMAs that 
were identical to the TRIFMAs except that the last antibody 
was labelled with 125r instead of a europium chelate. The 
TRIFMAs and IRMAs were reported to have similar detection 
limits, but the sensitivities of the former were generally 
higher than those of the latter. 
Determination of Miscellaneous Proteins. The remaining 
TRFIAs that have been developed (23,70-75,39, 77,78) are for 
human alpha-fetoprotein (hAFP) , sex-hormone binding globulin 
(SHBG), ovarian carcinoma-associated antigen determinant (CA 
125), a 34 kDa somatornedin binding protein (34 kDa SmBP), 







Prmciple of the indirect time-resolved fluoroimmunoassay for the detection of rotavirus 
Jn(! adenovirus in stool and RSV, paraint1uenzav1rus types 1, 2, and 3, influenza virus types A 
and B, and adenovirus in aspirates of nasopharyngeal secretions (nps) 
Figure 14. Schematic Diagram of the TRIFMA 
Procedure for the Determination 
of Viruses. From Reference (55). 
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~2-interferon, ferritin, placental protein 5 (PPS), and 
carcinoembryonic antigen (CEA). The determination of PLA 2 , 
published in 1983, was among the first TRIFMAs reported 
(74). It is unique in that it uses the same purified 
polyclonal antibody for both roles in the sandwich complex 
in a one-step procedure. No hook effect was reported 
although the imprecision was a little high (12%) at some 
points. 
71 
Alpha-fetoprotein is a glycoprotein produced mainly in 
the yolk sac and the liver. It is normally present at very 
low concentrations in adult serum and in large amounts in 
maternal serum and amniotic fluid. Elevated levels are also 
seen in certain fetal disorders and in carcinomas of the 
liver, germ cells, and gastrointestinal tract (70). A 
DELFIA-type noncompetitive TRIFMA for hAFP in serum and 
amniotic fluid was reported in 1985 (70). Purified 
monoclonal antibodies directed at two different antigenic 
determinants were employed. Both one- and two-step 
procedures were developed. The one-step procedure showed a 
hook effect at concentrations above 5000 IU/ml; all 
maternal serum samples are below this level so the one-step 
procedure can be used for them. Human AFP levels in 
amniotic fluid and tumor cancer patient specimens are often 
much higher than this, and should be measured with the 
two-step procedure. Chan and coworkers (23) developed a 
two-step TRIFMA for hAFP that uses the same biotin/ 
streptavidin CyberFluor system that was employed by Khosravi 
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and Diamandis (22) for the determination of hCG. The 
determination correlated well with the DELFIA hAFP deter-
mination (r = 0.98). The detection limits, working ranges, 
precisions, and analysis times of both TRIFMAs were very 
similar. Quite recently, a new CyberFluor TRIFMA of AFP was 
reported (34), in which streptavidin was indirectly labelled 
with BCPDA via a thyroglobulin carrier molecule. The 
analytical parameters for this TRIFMA were similar to those 
for the other CyberFluor TRIFMA for AFP. The only improve-
ment was that the new TRIFMA was a faster, one-step 
procedure. No hook effect was observed. 
A one-step TRIFMA for SHBG, without a hook effect, has 
been reported (71) and compared to several other immuno-
metric determinations of SHBG with respect to precision 
(76). The imprecision of both LKB and Farmos TRIFMAs was 
high compared to an IRMA. Only 77% and 82% of the respec-
tive TRIFMA samples had a coefficient of variation less than 
8%, while 100% of the IRMA samples fell into this category. 
Ferritin is a major intracellular iron-storage protein 
and its serum levels are a useful indicator of iron status 
in the body. The ferritin molecule consists of a protein 
shell of 24 very similar subunits and an interior core of 
ferric oxyhydroxide. Serum ferritin is usually measured by 
RIA or IRMA. A TRIFMA for the determination of ferritin 
which utilizes the CyberFluor system has been reported (39). 
The determination is a one-step procedure using monoclonal 
antibodies. A hook effect was observed at ferritin concen-
trations above 22 nM. A very low detection limit (1.1 pM) 
and low imprecision (<S%) were reported. The method was 
well correlated (r = 0.99) with an RIA technique based on 
double antibody separation. 
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A DELFIA TRIFMA has been used for the determination of 
placental protein 5 (PPS) in serum (77) using polyclonal 
antibodies. PPS is a glycoprotein that binds heparin and 
inhibits the action of plasmin and thrombin. Its action is 
linked to the blood coagulation system. The low levels of 
PPS in the serum and plasma of nonpregnant individuals are 
not detectable by RIA (detection limit around 1.2 pg/l). 
The two-step TRIFMA was able to detect PPS down to a level 
of 0.05 ~g/l with good precision. Good correlation (r = 
0.97) with RIA was found for higher concentrations of PPS. 
A TRIFMA for the determination of carcinoembryonic 
antigen (CEA) using a new terbium label has been reported 
(78). The fluorescence of the terbium can either be 
measured with the label bound to a solid surface while still 
in solution or after washing and an extraction step similar 
to the DELFIA system. Thus the labelling reagent (Tb-PPTA) 
can be used both as reagent of the first class and as a 
reagent of the second class. The fluorescence from the 
solid phase is an order of magnitude lower than that from 
the enhancement solution, which, is not used unless a lower 
detection limit is needed. The same antibodies were 
labelled with Eu(III1-(p-nitrophenoxy- carbonyl)DTPA in an 
effort to compare the two labels. The labelled antibodies 
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were found to have 8 Eu+3 and 11 Tb+3 per antibody. In 
enhancement solution, TRIFMA employing the Tb labelling 
reagent had a signal about 23% lower than that using the Eu 
labelling reagent. 
Conclusions 
This chapter has reviewed the use of time-resolved 
fluorescence in irnrnunochernical determinations of species of 
clinical interest. Time-resolved fluorescence is based on 
the application of time-gated detection of long-lived 
fluorescence in order to eliminate background signals. This 
technique was applied to immunochemical determinations in 
order to develop immunometric methods with detection limits 
below those currently achievable with radiochemical labels. 
Current TRIFMAs have detection limits that are the same as 
IRMAs or just slightly lower. TRIFMA detection limits 
should improve as the use of both indirect labelling systems 
with high fluorophore-to-antibody ratios and pulsed laser 
instruments increases. It is also quite conceivable that 
new fluorophors, with detection limits lower than those of 
currently used fluorophores, will be developed. 
The cost of changing the methods employed in clinical 
laboratories is very high. Switching to time-resolved 
f luoroimmunochemical methods is not currently justifiable if 
the decision is based solely on slight decreases in 
detection limits. On the other hand, if a laboratory is 
upgrading its facilities or just starting up, TRIFMAs are a 
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promising alternative to radioimmunochemical methods, 
especially since the handling of radioactive materials can 
be avoided. As the number of analytes that can be deter-
mined by commercially avaliable TRIFMA kits increases, more 
labs will probably begin to use this system. 
The DELFIA system has been applied to all three of the 
main types of immunochemical determinations. No other type 
of labelling system has reported a lower detection limit 
than that of Eu(~NTA) 3 (TOP0) 2 in TX-100. The CyberFluor 
system of TRIFMA seems to have only one advantage over the 
DELFIA system and this is its insensitivity to contamination 
by environmental europium. Otherwise its detection limits, 
working ranges and analysis times are about the same or a 
little worse than those of the DELFIA system. The new 
indirect labelling system used by CyberFluor should have 
lowered detection limits in its TRIFMAs but this was not 
evident from their data. _Until just recently, TRIFMA kits 
were available commercially from only one company, LKB-
Wallac, but Farmos Diagnostica and CyberFluor, Inc. -are now 
producing TRIFMA kits, also. Perhaps a little competition 
will result in a reduction in the price of these relatively 
expensive kits. 
Lastly, the use of TRPhIA for therapeutic drug 
monitoring should be compatible with the instrumentation 
developed for TRIFMA. If methods are found to increase the 
quantum yield of erythrosin, the detection limit of this 
method should decrease. TRPhIAs for haptens other than 
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drugs could then become commercially viable. The 
homogeneous TRFIA for haptens should soon become avaliable 
from LKB-Wallac and can be performed on the same instrument 
as the DELFIA kits. This should make the time-resolved 
approach to immunochemical determinations even more 
attractive to clinical laboratories. 
CHAPTER III 
PHASE-RESOLVED FLUORESCENCE SPECTROSCOPY 
AND ITS APPLICATION TO 
FLUOROIMMUNOCHEMICAL 
DETERMINATIONS 
Theory of Phase-Resolved Fluorescence 
Spectroscopy 
Phase-resolved fluorometry is based upon the phase-
modulation approach to fluorescence lifetime determin-
ations, in which the fluorescent sample is excited with 
sinusoidally-modulated light and observed with a phase-
sensitive detector. The theory and instrumentation of 
phase-modulation and phase-resolved fluorometry have been 
described in detail elsewhere (81-85). 
If a fluorescent sample is excited with sinusoidally-
modulated light, the resulting fluorescence emission is also 
sinusoidally modulated, but the is phase-shifted and demod-
ulated to an extent that depends on the fluorescence life-
time of the sample. The sinusoidal excitation has the form: 
E(t) =A ( 1 + mex sinlJt ( 2) 
where E(t) is the time-dependent intensity of the exciting 
light,(,.) is the angular modulatipn frequency(~= 21fl'f, where 
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f is the linear modulation frequency), A is the d.c. inten-
sity component of the exciting light and mex is the degree 
of modulation of the exciting light (the a.c.-to-d.c. 
intensity ratio). The resulting fluorescence emission has 
the form: 
F ( t) = A 1 [ 1 + mex m sin ( (,.) t - ~ ) J ( 3) 
where F(t) is the time dependent intensity of the fluor-
escence emission, A' is the d.c. intensity component of the 
emitting light, q, is the phase-shift of the emitting species 
and m is the demodulation factor. The relationship of the 
phase-shift and demodulation to the excitation and emission 
waveforms is shown in Figure 15. 
The lifetime ('l"') of the fluorescent species can be 
calculated from either the measured phase-shift (+) 
"r p = ( 1 I u'> ) tan ~ ( 4 ) 
or the demodulation 
')' m = 1 I "" [ ( 1 I m 2 ) - 1 JY11. ( 5) 
The excitation phase and modulation are calibrated by the 
use of a reference f luorophore solution of known lifetime or 
a scattering solution ('Y = 0). 
In phase-resolved fluorescence spectroscopy (PRFS) the 
time dependent (a.c.) component of the emission signal is 
observed with a phase-sensitive detector and integrated over 








Figure 15. Schematic Representation of the 
Excitation E(t) and Fluores-
cence F(t) Waveforms. From 
Reference (83). 
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half-cycle. The phase of the half-cycle is continuously 
0 0 
variable between 0 and 360 . The resulting phase-resolved 
fluorescence intensity (PRFI) has the form: 
= A' m m cos ex (~D - ~) ( 6) 
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where ¢ 0 is the position of the integration half-cycle (the 
detector phase angle setting) • If ~ 0 equals the phase of 
the time-dependent fluorescence emission (F(t)), the maximum 
PRFI is observed; if ~ 0 is 90D out-of-phase with F(t), the 
PRFI is zero; if ¢ 0 is between these two settings, 
intermediate values of PRFI are obtained. This is shown in 
Figure 16. F(¢ 0 ) is dependent on the wave- lengths and 
modulation frequency and is a function of the intensity, 
lifetime and concentration of the emtting species. For a 
multicomponent system of independent emitters, the PRFI 
contributions are additive. 
Review of Phase-Resolved 
Fluoroimmunochemical 
Determinations 
In Chapter II, the use of fluorescence lifetime 
differences between free and bound forms of fluorescent 
labelled immunochemicals in TRFIA and TRIFMA was described. 
Phase-resolved fluorescence spectroscopy was first applied 
to immunochemical determinations by Bright and McGown (86). 
They described the use of PRFS to determine free and 
l 































Figure 16. Depiction of the Periodic Interval 
Relative to F(t). From 
Reference (84). 
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antibody-bound fluorescein-labelled phenobarbital (Ag*) 
simultaneously in a homogeneous phase-resolved fluoroimmuno-
assay (PRFIA). The determination was based upon a small 
lifetime difference of 100 ps and a very small intensity 
change ( < 10%) between the free and bound Ag*. The PRFIA 
involved measurements made at a series of five non-nulling 
detector phase angles. Because PRFI contributions of non-
interacting emitters are additive, a series of linear 
equations were generated, of the form: 
( 7) 
rPRF = rF 
~ Cl>,. 
where rK,RF is the PRFI of a solution, I' is the PRFI of a 
solution containing only free Ag* and I~ is the PRFI of a 
* solution containing only antibody bound Ag for the first 
equation generated at ¢ D = ~1 • The set of equations is 
only valid if the total concentration of labelled antigen 
(CA*) is held constant for all of the solutions. In matrix 
form, these equations appear as: 
r~RF 





The over-determined matrix was "solved" for the fractions of 
free and bound Ag* using a least squares approach that 
included the constraint that the %free Ag* plus the %bound 
Ag* equal 100%. A typical calibration curve for the PRFIA 
determination of phenobarbital is shown in Figure 17. The 
PRFIA had a relative standard deviation of 6.7% for a set of 
four calibration curves. The limit of detection was found 
to be 3 pg/ml of phenobarbital in the undiluted sample. A 
homogeneous steady-state quenching approach was also tried, 
and the results obtained for the free Ag* were poorly 
correlated with the standard concentrations. 
A homogeneous PRFIA for the determination of human 
serum albumin was also reported (87). This work demon-
strated the applicability of PRFIA to the determination of 
macromolecules as opposed to haptens such as phenobarbital. 
Texas Red, a sulfonyl chloride derivative of sulforhodamine-
101, was used as the label. This species has a high molar 
absorptivity and quantum yield and a lower rate of photo-
bleaching than fluorescein. Also, its excitation and 
emission maxima are at 590 and 610 nm, respectively; these 
wavelengths are long enough to avoid most spectral inter-
ference from fluorescent species in serum. 
Because PRFI contributions are additive for independent 
emitters, the PRFI of an immunoassay standard or unknown 
solution takes the form of Eqn. 6. When the amount of Ag in 
a solution containing constant amounts of Ag* and Ab is 
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Figure 17. Typical PRFIA Calibration Curve for 
Phenobarbital. From Reference (84). 
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increased, the CAg* will increase by t::. C and CAg*-Ab will 
decrease by b.. C. Thus: 
B 
(CAg* + AC) + 1¢" (CAg*-Ab - b. C) ( 9) 
Subtraction of Eqn. 7 from Eqn. 9 gives 
6C= I' (\)n - Ic\Jn ] I ( I't\ - I~ ) ( 10) 
85 
Calibration curves were obtained by plotting AC as a func-
tion of CAg for a series of standard solutions. 
A fluorescence lifetime difference between the free and 
bound RSA of 0.090 ns was observed. No sample matrix 
effects were seen with serum samples, possibly due to the 
high dilution factor (7x10-6). A relative standard 
deviation of 5.8% was obtained for four calibration curves 
run on four consecutive days. The method was well corre-
lated with values obtained for 24 serum samples at a local 
hospital's clinical chemistry laboratory, using the bromo-
cresol green method (88) on a Technicon RA-1000 auto-
analyzer. 
The only other phase-resolved fluoroimmunochemical 
determination reported is a homogeneous, noncompetitive 
immunofluorometric determination of human lactoferrin (89). 
The method was based on energy transfer from f luorescein-
label led anti-lactoferrin (Ab*F) to tetramethylrhodamine-
labelled anti-lactoferrin (Ab*R) when both antibodies were 
bound to lactoferrin (Ag). The PRFI of the donor species 
(Ab*F) was measured and was found to decrease because of the 
energy transfer to Ag*R, in the presence lactoferrin, as a 
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function of the resulting decreases in both Ag*F intensity 
and lifetime. Energy transfer was not observed in the 
absence of lactoferrin. The data analysis was much less 
involved than in the previous PRFIA's: PRFI's were measured 
at only one detector phase angle, and the ratio of the PRFI 
of Ab*F in the presence of Ag to the PRFI in the absence of 
Ag was plotted as a function of CAg or log CAg" A pooled 
standard deviation of 8.39xlo-3 intensity ratio units was 
calculated for the points in a set of four cali- bration 
curves. The relative standard deviation was <2%. A hook 
effect was observed at high concentrations of Ag, so samples 
would need to be run at two different dilutions in order to 
get unambiguous results. 
CHAPTER IV 




Surfactants and cyclodextrins have been widely studied 
in recent years. Their ability to change the fluorescence 
characteristics of some molecules has been recognized as a 
valuable property and has potential applicability for 
immunoassays and immunometric determinations. 
Common surfactants are amphiphilic molecules with a 
hydrophilic head group and a long, hydrophobic tail; they 
can be classified as cationic, anionic, nonionic or zwitter-
ionic, depending on the nature of the hydrophilic group. 
Above a certain concentration, called the critical micelle 
concentration (CMC) , surfactant monomers associate to form 
spherical particles of colloidal dimensions. In aqueous 
solution, the interior of the micelle contains the hydro-
phobic moieties while the hydrophilic head groups are 
located at the surface of the sphere. Interaction between 
fluorophores and micelles can cause large changes in the 
fluorescence characteristics of the fluorophore. Fluoro-
phores generally associate with micelles in one of two ways, 
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depending on their relative hydrophobicity. They can adsorb 
on the exterior of the micelles in a primarily elec-
trostatic interaction with the surfactant head groups, or 
they can be absorbed into the hydrophobic interior of the 
micelles to some degree (90). 
Cyclodextrins are cyclic oligosacachrides composed of 
~-(1,4)-linkages of D(+)-glucopyranose units. The most 
common members of this family are o{-, (3-, and ¥-cyclo-
dextrins composed of six, seven, or eight glucose units, 
respectively. These molecules are torus shaped with a 
hydrophobic interior cavity. As the number of glucose units 
in the cyclodextrin increases, the diameter of the cavity 
increases from 4.5-6.0 (6 units) to 6.0- 8.0 (7 units) to 
0 
8.0-10.0 A (8 units) (91). The cyclodextrins can form 
inclusion complexes with organic molecules of suitable size 
and shape. Larger molecules can form inclusion complexes if 
they have an aromatic moiety or other group that can fit 
into the cyclodextrin cavity. The interactions between the 
cyclodextrin and the included compound are largely due to 
van der Waals forces and hydrophobic interactions. 
Absorption spectra of aqueous solutions of the inclusion 
complexes are often different than those of the unbound 
solutes in aqueous solutions. Cyclodextrins are believed to 
enhance the fluorescence of certain fluorophores by 
inhibiting the quenching effects of aqueous solutions. 
In heterogenous fluoroimmunochemical determinations, 
micelles or cyclodextrins could be used to increase the 
fluorescence intensity of the free fraction of the 
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fluorescent-labelled species after removal of the bound 
fraction in order to improve the detection limits. This 
approach was used in the TRIFMA systems reviewed in Chapter 
II. Micelle-induced spectral shifts could be of value in 
avoiding spectral interferences due to constituents in the 
sample matrix. The modification of fluorescence properties 
by micelles or cyclodextrins could also be exploited for 
homogeneous fluoroimmunochemical determinations to improve 
the discrimination between the free and bound fractions of 
the labelled species. For example, the use of sodium 
dodecyl sulfate, an anionic micellar species, to increase 
the fluorescence intensity and polarization differences 
between free and Ab-bound fluorescein-labelled gentamicin 
has been incorporated into a solvent-perturbation FIA 
technique (92). A similar approach was used for the 
determination of methamphetamine (93). If micelles and 
cyclodextrins increase the differences in the fluorescence 
characteristics of free and antibody-bound fluorescein-




Fluorescein-labelled phenobarbital (Ag*) was prepared 
in situ by Bright, Bunce and McGown (94). The 
dodecylamine hydrochloride (DAC) and dodecyltrimethyl-
ammonium chloride (DTAC) were purchased from Eastman, and 
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the hexadecyltrimethylammonium chloride {CTAC), tetradecyl-
trimethylammonium bromide {TTAB) and N,N-dimethyldodecyl-
amine-N-oxide (LDAO) from Fluka. Triton X-100 (TX-100) and 
beta-cyclodextrin (~-CD) were purchased from Sigma and 
gamma-cyclodextrin {~-CD) was purchased from ICN 
Biochemicals. Sheep anti-phenobaTbital antibodies {Ab) were 
-
purchased from Cambridge Medical Diagnostics. A protein 
concentration was not supplied with the Ab; thus, all 
concentrations of Ab in solution are reported as µl added of 
1:500 dilution of Ab in 0.010 M, pH 7.4 phoshate buffer. 
All compounds were used without further purification. 
Demineralized, distilled water was used for all 
preparations. The Ag* stock solution was prepared by 
100-fold dilution of the chromatographically purified 
reaction product. The concentration of the stock solution 
was estimated to be 30 µM by using a calibration curve 
generated with fluorescein isothiocyanate {Sigma). 
Unbuffered solutions of all surfactants were prepared at 
concentrations above their reported CMC values (95,96) and 
mixed by ultrasonic treatment for 30 minutes. Cyclodextrin 
solutions were similarly prepared. The concentrations of 
these solutions are given in Table VII. Buffered solutions 
of the surfactants were prepared at the same concentrations 
as the unbuffered solutions, in 0.010 M sodium phosphate 
buffers ranging in pH from 5.8 to 7.8. Constant ionic 
strength (µ = 0.10 M) buffered solutions of TTAB were 
prepared by addition of the appropriate amount of sodium 
chloride. 
For the studies of free Ag*, the analytical concen-
tration of Ag* in the cuvette was calculated to be 0.21 pM 
from the estimated concentration of the Ag* stock (see 
above). In the Ag*-Ab studies, Ag* stock solutions (3 x 
10-6 M, 3 x 10-7 M) were prepared by diluting the the 
appropriate volume of Ag* with phosphate buffer. 
Apparatus and Procedures 
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All fluorescence measurements, including steady-state 
intensities and dynamic phase-shifts and demodulations, were 
made with an SLM 4800$ Spectrofluorometer in ratiometric 
modes, with a portion of the excitation beam diverted to a 
reference photomultiplier to compensate for fluctuations in 
the source output and (for dynamic measurements) excitation 
modulation. A 450-W xenon arc lamp was used for excitation, 
Hamamatsu R928 photomultipliers for detection and an Apple 
II+ microcomputer for on-line aquisition of fluorescence 
spectral and lifetime data and for lifetime calculations. A 
block diagram of the SLM 48008 is shown in Figure 18. 
For dynamic measurements, slits were set at 16 nm and 
0.5 nm band-pass for the excitation monochromator entrance 
and exit, respectively, 0.5 nm for the modulation tank exit, 
and 16 nm for both the entrance and exit of the emission 
monochromator. In studies where low concentrations of 
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filter (10 nm half-width, Oriel) was used instead of the 
emission monochromator. In the micellar studies, all slits 
were set at 2 nm band-pass for steady-state intensity 
measurements, except for the excitation monochromator 
entrance slit which was set at 16 nm. An excitation 
,, 
polarizer set at 35 from the vertical axis was also used in 
the micelle studies. In the cyclodextrin studies, steady-
state excitation and emission spectra were obtained with 
slit settings of 8 nm for the excitation monochromator 
entrance and exit and the modulation tank exit, and 16 nm 
for the emission monochromator entrance and exit. 
Polarization studies were performed with an excitation 
0 
polarizer set at 0 from the vertical axis and an emission 
polarizer set first at 0° and then at 90• from the vertical. 
Slits were set at 8 nm for the excitation entrance and exit 
and 4nm for the modulation tank exit. The 530 nm bandpass 
filter was used instead of the emission monochromator. 
Polarization was calculated using the following equation: 
p = ( I II - I.lo ) I ( I II - I..l. ) ( 11) 
where P is the fluoresce~ce polarization, I 11 is the fluor-
escence emission intensity with the excitation and emission 
polarizer parallel to each other and I~ is the fluorescence 
emission intensity with the excitation and emission 
polarizers set perpendicular to each other. 
Temperatures in the fluorometer sample chamber were 
• • 0 0 • 
maintained at 25 ..±. 0.1 with a Haake A81 temperature control 
unit. Disposable polyethylene cuvettes (Precision Cells) 
were used to contain solutions for fluorescence measure-
ments. 
Unless otherwise noted, the fluoresence lifetimes of 
Ag* were determined relative to a reference solution of 
Acridine Orange in absolute ethanol (U.S. Industrial 
Chemical Co.), which was found (from phase-shift measure-
ments) to have a lifetime of 3.19 ± 0.02 ns relative to a 
scattering solution, at the wavelengths used in this work. 
Equations for these calculations were described in 
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Chapter III. All fluorescence lifetimes are reported as the 
average of five measurements taken in the "100 average" 
mode, in which each measurement is the average of 100 
samplings performed internally by the spectrofluorometer. 
Absorption spectra were acquired with a Perkin-Elmer 
Lambda Array 3840 Spectrophotometer. 
Effects of Micelles and Cyclodextrins on 
Fluorescein-Labelled Phenobarbital 
Results and Discussion 
All of the fluorescence lifetimes reported here had 
standard deviations in the 5-50 ps range . A lifetime of 
4.04 ns had previously been found for Ag* by using phase-
shift measurements (86). 
The effects of five micelle-forming species and of~­
and ~-cyclodextrin are summarized in Table VII. The pH 
values of each of the unbuffered micellar solutions are also 
listed. All five micellar species caused red shifts ranging 
Added Species a 
none 
CTAC ( 3 . 0) 
DAC ( 15) 
DTAC (22) 
LDAO (4.0) 




EFFECTS OF MICELLES AND CYCLODEXTRINS ON THE FLUORESCENCE 
PROPERTIES OF FLUORESCEIN-LABELLED PHENOBARBITAL (Ag*) 
A em' max b Intensity Ratio 'I p d 'Y m 
e 
516 1. 00 4.00g 4.oog 
526 2.64 4.39 4.45 
523 1.36 4.07 4.23 
526 2.54 4.28 4.30 
522 1.05 3.68 3.86 
525 2.72 4.40 4.44 
516 2.05 4.15 4.12 
517 1. 57 4.23 4.07 
a Concentration in parentheses, mM. 







c Ratio of intensity in presence of the added species to that in its absence, each 
measured at its emission maximum. 
d Fluorescence lifetime calculated from phase-delay, in ns, determined using the Ag* 
solution as a reference ('I= 4.00 ns). 
e Fluorescence lifetime calculated from the demodulation, in ns, determined in the same 
manner as p. 
f pH of the cuvette solution. Dash indicates pH not determined. 




from 5 to 10 nm in the emission of Ag*. No shifts in the 
emission maximum were observed with the cyclodextrins. 
Fluorescence enhancement was observed with all species, and 
was highest with CTAC, DTAC, and TTAB. All species except 
LDAO, which was the only nonionic micelle used, caused 
increases in the observed lifetime. CTAC, TTAB and 
~-cyclodextrin were chosen for further studies. 
A shift in the emission maximum of Ag* to 526 nm was 
observed with both CTAC and TTAB at all pH values studied, 
indicating an absence of pH-dependence. Fluorescence 
enhancements .of Ag* in CTAC and TTAB as a function of pH are 
shown in Table VIII. Enhancements are expressed as 
peak-to-peak values (i.e., the ratio of the intensity of 
micelle-Ag* to that of Ag*, each measured at its emission 
maximum). A small trend towards increased enhancement was 
observed as the pH decreased, with a dramatic increase at 
pH 5.8. 
Absorption spectra of Ag* and TTAB-Ag* at pH 5.8 are 
shown in Figure 19. The spectra show a definite increase in 
absorptivity in the presence of TTAB, indicating that the 
so-called fluorescence enhancement is at least partially due 
to absorption rather than quantum yield changes. For 
simplicity, the fluorescence intensity increases will 
continue to be referred to as enhancements. 
The fluorescence lifetime difference of 0.3 ns between 
micelle-Ag* and Ag* remained fairly constant over the pH 
range studied for Ag* in the presence of both CTAC and TTAB. 
TABLE VIII 
RATIOS OF THE INTENSITY OF Ag* IN THE PRESENCE OF 
MICELLES TO THE INTENSITY IN THE ABSENCE OF 
MICELLES AS A FUNCTION OF pH 
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pH Intensity Ratio (CTAC) Intensity Ratio (TTAB) 
5.8 6.24 5.12 
6.0 2.29 1.35 
6.2 1. 39 1. 80 
6.4 1.17 1.30 
6.6 1.41 1.39 
6.8 1.03 1. 26 
7.0 1. 05 1.20 
7.2 1. 01 1.07 
7.4 0.91 0.91 
Ratios of intensities measured at A = 490 nm and at the 
emission maxima for that solution, 58th measured under the 
same buffer and pH conditions. 
420 440 460 480 500 520 540 560 
WAVELENGTH, nm 
Figure 19. Absorption Spectra of Fluorescein-Labelled 
Phenobarbital with TTAB and without TTAB in 
Buffered Solution at pH 5.8. 
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The effects of TTAB on Ag* fluorescence were studied in 
buffered solutions adjusted to 0.010 M ionic strength with 
sodium chloride. Differences between the fluorescence 
lifetime~ of TTAB-Ag* and Ag* as a function of pH are shown 
in Table IX. The change in lifetime calculated from the 
demodulation remained fairly constant, but the change in 
lifetime calculated from the phase-shift showed a definite 
increase with decreasing pH. 
The effects of pH on the relative intensities of Ag* 
and TTAB-Ag* are shown in Figure 20, and the ratios of the 
intensities are listed in Tabl~ IX. Smaller relative 
enhancements were observed for the constant ionic strength 
solutions than for the buffered solutions without sodium 
chloride added (Table VIII). 
Fluorescein is a weakly acidic molecule, with pKal and 
pKa 2 values of 4.4 and 6.7, respectively (97). The 
completely dissociated form is highly fluorescent, and the 
fluorescence intensity of fluorescein solutions increases 
with increasing pH. As shown in Figure 20, in the low pH 
range, the fluorescence of Ag* is enhanced by associacion 
with TTAB, but above pH 7.2 TTAB causes a decrease in 
intensity relative to that in the absence of the micelle, 


















THE INTENSITY RATIOS OF TTAB-Ag* TO Ag* AND THE 
DIFFERENCES BETWEEN THE FLUORESCENCE LIFETIMES 
OF THE TWO AS A FUNCTION OF pH, IN CONSTANT 
IONIC STRENGTH SOLUTION 
Intensity Ratio a ,... b p 1"' m 
1. 38 0.37 0.43 
1.30 0.37 0.52 
1.15 0.36 0.46 
1.11 0.29 0.46 
1.19 0.35 0.44 
1. 30 0.31 0.45 
1. 07 0.29 0.46 
0.98 0.33 0.46 
0.98 0.26 0.46 
0.97 0.27 0.44 
0.88 0.26 0.47 
100 
c 
Intensities measured at "A = 490 nm, and at the emission 
maximum of the solution, 58th at same pH. 
Fluorescence lifetime of TT AB-Ag* minus that of Ag* as 
calculated from the phase-shift lifetimes, in ns. 
Fluorescence lifetime of TT AB-Ag* minus that of Ag* as 
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5.4 6.0 6.6 
pH 
7.2 7.8 
Figure 20. Fluorescence Intensity of Ag* (t ) and 
TTAB-Ag* (~) as a Function of pH in 





excitation and emission spectra of Ag* with and without TTAB 
at pH 5.8 and pH 7.0 are shown in Figure 21. The ratio of 
the intensity of TTAB-Ag* to that of Ag*, measured at the 
wavelength maxima for the latter (~ex= 501 nm and ~em= 
525 nm) was found to be 2.7 at pH 5.8 and 1.7 at pH 7.0. 
The fluorescence wavelength maxima and lifetimes of Ag* 
as a function of TTAB concentration were studied at pH 5.8 
(Table X). Spectral shifts are almost negligible at TTAB 
concentrations below 0.6 mM. Fluorescence lifetimes 
decrease with increasing TTAB concentration up to around 
1 mM, when they jump to a higher value that remains constant 
at higher concentrations. The initial decrease in lifetimes 
indicates quenching of the Ag* fluorescence at TTAB concen-
trations below its CMC. Above the CMC, the lifetimes 
achieve a maximum value corresponding to that of Ag* 
protected by micelle association. Table XI shows the 
results of a similar study at pH 7.0. Simliar trends are 
observed in the emission maxima and lifetimes, but the 
transitions occur at slightly lower TTAB concentrations. 
Relativ~ intensities are also shown for both pH values, and 
indicate that there is indeed a quenching effect at TTAB 
concentrations below the apparent CMC. 
The effects of ~-CD on the fluorescence lifetime and 
polarization of Ag* at pH 7.4 were studied. The fluor-
escence lifetime of Ag* was measured over a ~-CD range of 2 
x 10-7 to 2 x 10-3 M. At low concentrations ~-CD had no 






A = TTAB-Ag* excitation, B = Ag* excitation 
C = TTAB-Ag* emission, D = Ag* emission 
Note: The Intensity scales for the spectra at 
pH 7.0 and 5.8 are different. The 
intensity at 7.0 is higher. 
Figure 21. Excitation and Emission Spectra of Ag* 
with and without TTAB in Constant 









FLUORESCENCE EXCITATION AND EMISSION MAXIMA AND THE 
DIFFERENCE BETWEEN THE FLUORESCENCE LIFETIMES 
OF TTAB-Ag* AND Ag* AS A FUNCTION OF TOTAL 
TTAB CONCENTRATION IN pH 5.8, CONSTANT 
IONIC STRENGTH SOLUTIONS 
CTTAB 
a ). b A em c IP a ex 
0 491 517 
0.46 492 518 0 
0.58 492 518 -0.13 
0.69 496 525 -0.27 
1.0 502 525 0.32 
3.1 501 525 0.36 
7.0 501 525 0.36 
Analytical concentration of TTAB, in mM. 
Excitation maximum, in nm. 
Emission maximum, in nm. 
See ( b) , Table IX. 
See ( c) , Table IX. 














FLUORESCENCE EMISSIOM MAXIMA, INTENSITY RATIOS AND THE 
DIFFERENCE BETWEEN THE FLUORESCENCE LIFETIMES OF 
TTAB-Ag* AND Ag* AS A FUNCTION OF TOTAL TTAB 
CONCENTRATION IN pH 7.0, CONSTANT 
IONIC STRENGTH SOLUTION 
CT TAB 
a ). b 
em Intensity Ratioc 
0 516 
0.69 521 0.28 
0.81 525 0.42 
0.91 525 0.75 
1. 0 525 0.84 
3.1 525 
7.0 525 1.07 
Analytical concentration of TTAB, in mM. 

















Ratio of the intensity of TTAB-Ag* to Ag*, measured at 
~ . = 490 nm and at the emission maximum of the 
ex . so1ution. 
See (b), Table IX. 
See (c), Table IX. 
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of ~-CD to Ag* was greater than 100,000 to 1, the lifetime 
began to increase and was still increasing at a concen-
tration ratio in excess of 8 x 105 : 1, as illustrated in 
Figure 22. This figure shows that fluorescein-labelled 
phenobarbital does not associate with ~-CD until the 
cyclodextrin is in great excess, indicating a fairly weak 
interaction between the two species. The effect of p-cD on 
the polarization of a 1.9 nM Ag* solution is shown in Figure 
23. The polarization increases with increasing concentra-
tion of ~-CD up to a concentration of about 2.0 mM. This 
concentration is at a ~-CD to Ag* concentration ratio of 
approximately 1.7 x 106 : 1. Because of the very weak 
interaction between Ag* and ~-CD it is extremely unlikely 
that an inclusion complex is being formed. Phenobarbital is 
known to form inclusion complexes with ~-CD (98), but it is 
bound via the aromatic ring. The fluorescein-labelled 
phenobarbital used in this work (see Figure 24 for the 
structure of Ag*) is labelled at the para position of the 
aromatic ring, preventing inclusion of this moiety. The 
fluorescein end of the Ag* is too large to fit into ~-CD. 
Conclusions 
Changes observed in Ag* fluorescence upon association 
with micelles included pH-independent spectral shifts and 
pH-dependent fluorescence intensity and lifetime changes. 
Cyclodextrins did not induce spectral shifts in the Ag* 
fluorescence, and the induced lifetime changes were not as 
3.7 




1.5 2.5 3.5 4.5 5.5 
Log (CAg*/C {i-CO} 
Figure 22. Fluorescence Lifetime of Ag* as a 
Function of Log (CAg* I C~-CD) 













0.030 -lf0 '----r----,----,-........ - ........ ----,---....----.---..----. 
0 5 1 0 1 5 20 25 
Cone. p-CD (M, x 1 E-4) 
Figure 23. Fluorescence Polarization of 1.9 nM Ag* 










large as those observed for the micelle systems. However, 
large intensity enhancements were observed that might prove 
valuable in certain applications. Future research into the 
applications of auxillary binding reagents will require 
studies on the antibody-bound as well as the free labelled 
antigen. Therefore, it is difficult to predict which 
reagents will prove most valuable for a particular 
immunoassay technique. The studies described here 
demonstrate that significant changes in the fluorescence 
properties of fluorescein-labelled phenobarbital can be 
acheived by using micelles, and to a lesser degree, 
cyclodextrins. 
Effects of Micelles and Cyclodextrins on 
Antibody-Bound Fluorescein-Labelled 
Phenobarbital 
Results and Discussion 
The interactions of micelles and cyclodextrins with 
Ag*-Ab, at the same auvillary binding reagent concentrations 
as used in the studies of free Ag*, were also investigated. 
The effect of Ab on Ag* in pH 7.4 phosphate buffer solution 
is used as a comparison in evaluating the effects of 
micelles and cyclodextrins. Various antibody preparations 
were compared. 
in Chapter v. 
The results of these studies are discussed 
The antibody preparation that gave the best 
results was used in subsequent studies. 
The lifetime difference between Ag* and Ag*-Ab was 
found to be 0.37 ns in buffer solution. The effect of 
various micelles on the lifetime difference and the 
intensity ratio of Ag* to Ag*-Ab are shown in Table XII. 
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The lifetime difference between Ag* and Ag*-Ab decreased 
substantially in the presence of the micelles. The smallest 
b"'r was seen in the presence of LDAO, and the largest A"r 
was observed in the presence of TX-100. The intensity ratio 
of Ag* to Ag*-Ab was lower in the presence of the micelles 
than in their absence. The TX-100 micelles had the highest 
intensity ratio of all the micelles studied. No spectral 
shifts between the free and bound Ag* were seen in the 
presence of the micelles. These results show that the 
micelles actually decrease the ability to discriminate 
between the free and antibody-bound fluorescein-labelled 
phenobarbital. 
The fluorescence excitation and emission spectra of Ag* 
in 2 mM ~-CD in the presence and absence of Ab are shown in 
Figure 25. The excitation and emission maxima are 
essentially the same as in the absence of ~-CD, as shown in 
Table XIII. The fluorescence intensities of both the free 
and bound Ag* are higher in ~-CD than in buffer solution 
(Table XIII), although the intensity ratio of Ag* to Ag*-Ab 
at 520 nm was larger for the buffer solution. 
The fluorescence polarization of Ag* as a function of 
the volume of Ab added is plotted in Figure 26 for 1.9 nM 





EFFECTS OF MICELLES ON THE FLUORESCENCE 
LIFETIME DIFFERENCES AND INTENSITY 
RATIOS BETWEEN Ag* AND Ag*-Ab 
112 
Added Species a ~"I F-B 
b Intensity Ratioc 
none 0.37 2.02 
CTAC ( 3 • 0) 0.08 1.04 
TTAB ( 7. 0) 0.09 1. 02 
LDAO ( 4. 0) 0.13 1. 35 
TX-100 (0.25) 0.30 1. 85 
Concentration in parentheses, mM. 
Fluorescence lifetime of Ag* minus that of Ag*-Ab as 
calculated from the phase-shift lifetimes, in ns. 
Ratio of the intensity of Ag* to Ag*-Ab, measured at 


















Figure 25. Fluorescence Excitation and Emission 
Spectra of Ag* in 2 mM (3 -CD in the 
Presence (----) and Absence (---) of 










EFFECT OF ~-CD ON THE SPECTRAL CHARACTERISTICS 
OF Ag* AND Ag*-Ab 
A ex, max a I maxb A em' 
a max c I max 
492 789 518 652 
496 405 520 322 
494 878 518 717 
494 522 520 420 
a Wavelength of maximum intensity, in nm. 
't t' d Intensi y Ra io 
2.02 
1. 71 





Emission intensity measured at the emission maximum, arbitrary units. 
Ratio of the emission intensities of Ag* to Ag*-Ab, measured at ~ex = 494 nm and 
Aem = 520 nm. 
0.010 M phosphate buffer, pH 7.4 
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0 20 40 60 80 1 00 
Volume of 1/500 Ab added (ul) 
Figure 26. Fluorescence Polarization of 1.9 nM Ag* at 
pH 7.4 as a Function of Volume of 1:500 
Ab added in·· both 2 mM (J-CD ( t ) and 
Phosphate Buffer ( a ) . 
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both cases, the polarization increases with increasing 
volume of Ab added. The points fall roughly on the same 
curve indicating no real advantage from including the ~-CD 
in the system. The effect of r-CD on the fluorescence 
lifetime of Ag* over a range of Ag* concentrations was 
studied as a function of volume of Ab added. The results 
are shown in Figure 27. The difference in fluorescence 
lifetimes between the free and completely bound Ag* was 
approximately 0.44 ns except for a difference of 0.39 ns for 
the highest Ag* concentration (11.6 nM). The Ag* may not 
have been completely bound at this concentration. As the 
concentration of Ag* decreased from 11.6 to 1.2 nM the slope 
of the curves increased. In the buffer solution without 
~-CD, the curves for the same range of Ag* concentrations 
(in Chapter V) all tend to level out at about the same 
lifetime value. But in the presence of 2mM ~-CD, the curves 
for 1.2 and 1.9 nM Ag* level out at lifetime values that are 
higher than expected: the 1.2 nM Ag* curve levels out about 
0.10 ns higher than expected and the 1.9 nM Ag* curve at 
0.04 ns higher. Th~s effect indicates that ~-CD plays a 
more predominant role at low concentrations of Ag* than at 
higher Ag* concentrations. The ~-CD causes the system as a 
whole to have a higher overall lifetime but with a more 
pronounced effect when almost all of the Ag* is bound by the 
antibody. 
The effect of (-CD on the fluorescence lifetime of Ag* 






















3.2-t-~~.,.-~~r--~--,~~--,..~~~ ..... ~:...,....~--. 
0 20 40 60 80 100 120 140 
Volume of 1/500 Ab added (uL) 
Figure 27. Antibody Dilution Profile in which Fluor-
escence Lifetime is Plotted as a Function 
of the Amount of 1:500 Dilution of Ab 
Added for a Series of Ag* concentrations 
in 2 mM, pH 7. 4 ~-CD. 11 • 6 nM ( El ) , 
5. 0 nM ( + ) , 1. 9 nM ( • ) , 1. 2 nM ( 0 ) Ag*. 
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~-CD and phosphate buffer at a 1.9 nM Ag* concentration. 
Figure 28, in which the fluorescence lifetime is plotted as 
a function of the volume of 1:500 Ab added for 2 mM ¥-CD, 2 
mM ~-CD and phosphate buffer, shows that the solutions l-CD 
have a smaller lifetime difference between free and bound 
Ag* than either the~-CD or phosphate buffer solutions. The 
lifetime difference was found to be 0.32 ns. 
Conclusions 
The various micelles studied tended to have a 
detrimental effect on the ability to discriminate between 
the free and antibody-bound fluorescein-labelled 
phenobarbital. They increased the overall intensity of the 
system but decreased the intensity ratio of Ag* to Ag*-Ab 
relative to the intensity ratio in buffer solution. The 
least detrimental effects were seen in the presence of 
TX-100. The fluorophore seems to be adsorbed on the surface 
of the micelles thus allowing the micelles to associate with 
both Ag* and Ag*-Ab. The micelles may also denature the 
antibody to a certain extent. Micelles are not useful in 
the present PRFIA system but may be useful in a PRFIA with 
more hydrophobic labels and/or antigens. 
The cyclodextrins had a much smaller effect on the 
Ag*-Ab than the micelles, showing only slight increases in 
overall lifetime and intensity of the system. The intensity 
ratio of Ag* to Ag*-Ab for both~-CD and ~-CD was lower than 
-f/j c -
Cl) 


















40 60 80 100 120 
Volume of 1/500 Ab added (uL) 
Figure 28. Fluorescence Lifetime of 1.9 nM Ag* as 
a function· of the· .Amount of 1:500 Ab 
added for 2mM o -CD ( t:l ) , 2 mM (.3-CD 
( • ) , and phosphate buffer ( • ) at 
pH 7.4. 
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that found in buffer solution, although the intensity ratio 
was sti 11 fairly high in ~-CD; on the other hand, f.>-CD 
increased the lifetime difference between the free and 
antibody-bound Ag* slightly with respect to the buffer 
solution. However, these two effects tend to cancel each 
other out and therefore, 0-CD is not very useful for the 
present PRFIA of phenobarbital. The cyclodextrins may be 
useful in PRFIA's with smaller, more hydrophobic labelled 
antigens. 
CHAPTER V 
OPTIMIZATION OF EXPERIMANTAL CONDITIONS IN 
THE PRFIA FOR THE DETERMINATION 
OF PHENOBARBITAL 
Introduction 
Fluoroimmunoassays {FIA) are widely used alternatives 
to radioimmunoassays {RIA) in the field of therapeutic drug 
monitoring. Unlike radioisotopes, fluorophores are 
sensitive to their chemical microenvironment enabling one to 
develop homogeneous {nonseparation) immunoassays. Any of 
several different fluorescence characteristics may change 
when the antibody binds to the labelled antigen. Homo-
geneous FIAs can take advantage of changes in fluorescence 
intensity, energy transfer, polarization, and fluorescence 
lifetimes (2-5). Both phase-resolved fluoroimmunoassays 
(PRFIA) and time-resolved fluoroimmunoassay {TRFIA) are 
based on fluorescence lifetimes; however, PRFIAs use fluor-
escence lifetimes to help in the discrimination between free 
and bound Ag*, while TRFIAs only use fluorescence lifetime 
differences to eliminate background fluorescence. PRFIAs 
may be either homogeneous or heterogeneous while, with two 
exceptions, all reported TRFIAs are heterogeneous {27,28, 
44). The homogeneous TRFIAs were based on fluorescence 
intensity differences between the free and bound Ag*; only 
121 
122 
PRFIAs use fluorescence lifetime selectivity as the basis of 
homogeneous detection. The first PRFIA was developed for 
the determination of phenobarbital (86). The phase-resolved 
technique was subsequently applied to the f luoroimmuno-
chemical determination of human serum albumin (87) and human 
lactoferrin (89). 
Phenobarbital was chosen as a model analyte for the 
initial development of PRFIA. Like other barbiturates, it 
acts upon the central nervous system as a suppressor of 
neuronal activity. Phenobarbital is used as a hypnotic and 
an anticonvulsive. Its therapeutic level is fairly narrow, 
ranging from 10 to 40 pg/ml. Serum levels between 40 and 
about 100 µg/ml are toxic but nonlethal. Concentrations 
above 100 pg/ml are usually considered lethal, although this 
level is not absolute since tolerance can occur (99-101). 
In addition, equivalent dosages do not produce equivalent 
serum levels from patient to patient. Thus, serum concen-




Fluorescein-labelled phenobarbital (Ag*) was prepared 
in situ, .see Chapter IV, (94) and the concentration of the 
chromatographically purified reaction product was estimated 
to be 30 uM (102). A preparation of anti-phenobarbital was 
obtained as gift from Syva. Goat anti-phenobabital was 
obtained from International Immunology Corporation 
(Murrieta, CA) and sheep anti-phenobarbital (Ab) was 
purchased from Cambridge Medical Diagnostics (Billerica, 
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MA) • A protein concentration was not supplied with this Ab, 
thus all concentrations of this Ab in solutions are reported 
as µl of 1:500 dilution of Ab in 3.0 ml of buffered 
solution. Phenobarbital (Ag), Triton X-100, and pooled human 
sera were all purchased from Sigma Chemical Company. The 
pooled human sera was supplied as a lyophilized solid and 
reconstituted according to the manufacturer's instructions. 
Al 1 compounds were used without further purif_ication. 
Demineralized, distilled water was used for all 
preparations. Phosphate buffer was prepa~ed from NaH2Po 4 
and Na 2HP04 solutions and contained 0.1% sodium azide as a 
preservative. The Ab stock solution was a 1:500 dilution of 
the Ab in phosphate buffer. The Ag* stock solutions 
(3x10-6, 3xlo-7 M) were prepared by diluting the appropriate 
volume of Ag* with phosphate buffer. The pooled human sera 
was diluted 300-fold with phosphate buffer. The Ag stock 
solution (2.0xlo-3 M) was prepared by dissolving the Ag in 
phosphate buffer and sonicating for one hour. A series of 
phenobarbital solutions were prepared by diluting the 
appropriate volume of Ag stock solution with 1:300 pooled 
human sera (or phosphate buffer for solutions without human 
sera). Standards and test solutions were prepared by the 
addition of 35 pl of 3xlo-7 M Ag*, 50 µl of Ag of the 
appropriate concentration, and 35 pl of Ab to a cuvette 
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containing 2880 pl of 0.010 M phosphate buffer (pH 7.4, 
0.010% TX-100) and incubating for one hour. The buffer 
solution containing the TX-100 was added to the cuvettes one 
day prior to preparing the standards and test solutions. 
Triton X-100 was used to prevent adsorption of the 
f luorophore onto the sides of the disposable polyethylene 
cuvettes (Precision Cells). 
Apparatus and Procedures 
All fluorescence measurements were made with an SLM 
4800S spectrofluorometer (SLM Instruments, Inc.) with 450 W 
xenon arc source and photomultiplier tube (Hamamatsu R928) 
detection. An Apple Ile microcomputer was used for on-line 
data acquisition and for data analysis. An excitation 
modulation frequency of 30 MHz was used for all dynamic 
measurements. The sample compartment temperature was 
0 • • 
maintained at 25.0 z 0.1 C with a Haake A81 temperature 
control unit. All fluorescence lifetimes are reported as 
the average of five measurements taken in the "100 average" 
mode, in which each measurement is the average of 100 
samplings performed internally by the spectrofluorometer. A 
solution of acridine orange (U.S. Industrial Chemical Co.) 
in absolute ethanol was used as the reference for all direct 
lifetime measurements. The fluorescence lifetime of 
acridine orange was found to be 3.19 ± 0.02 ns versus a 
scatter solution. Steady state emission and excitation 
spectra were obtained in the "10 average" mode with slit 
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settings of 8 nm for the excitation monochromator entrance 
and exit and the modulation tank exit slits, and 16 nm for 
the emission monochromator entrance and exit slits. All 
other fluorescence measurements were made with the exci-
tation monochromator entrance slit at 16 nm, the excitation 
monochromator exit slit at 0.5 nm, the modulation tank exit 
slit at 0.5 nm and a 530 nm bandpass filter (10 nm half-
width, Oriel) instead of the emission monochromator. 
Results and Discussion 
Three different anti-phenobarbital preparations were 
studied. The first was a gift from Syva. No change in 
fluorescence intensity or lifetime was seen when this 
antibody was added to a solution of the fluorescein-labelled 
phenobarbital. Either the antibody was not binding the Ag* 
or it was just not producing any detectable changes in the 
fluorescence characteristics of the Ag* upon binding. The 
second antibody preparation was goat anti-phenobarbital from 
International Immunology. It produced a 0.10 ns lifetime 
difference between the free and bound Ag*. The third 
antibody preparation was sheep anti-phenobarbltal from 
Cambridge Medical Diagnostics. It produced the largest 
lifetime change and also a large intensity change between 
the free and bound Ag*. This antibody was used in the 
remainder of the current work. 
Spectra of free Ag* and completely Ab-bound Ag* are 
shown in Figure 29. The fluoresence intensity of the Ag* is 
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~ i.gure 29. Fluorescence Excitation and Emission 
Spectra of Free (Ag*) and Antibody-
Bound (Ag*-Ab) Labelled Phenobarbital 
in Phosphate Buffer Solution at pH 7.4. 
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quenched when the antibody binds the Ag*. The ratio of the 
fluorescence emission intensities at 525 nm of the free to 
* the bound Ag was 2.7. The excitation and emission maxima 
remain constant, with the excitation maximum at 490 nm and 
the emission maximum at 525 nm. 
The fluorescence lifetime of Ag*, as a function of the 
volume of Ab added is plotted in Figure 30 for four dif-
ferent concentrations of Ag*. In all cases, the differ-
ence in fluorescence lifetime between the free and com-
pletely bound Ag* was approximately 0.35 ns. As the 
concentration of Ag* decreased from 11.6 nM to 1.2 nM, the 
slope of the curves increased. Thus, lower concentrations 
of Ag* require less Ab to become N50% bound and, conse-
quently, the introduction of a small amount of Ag into the 
system induces a larger change in the fluorescence signal in 
* the immunoassay that uses a lesser amount of Ag . However, 
the signal to noise ratio decreases as the concentration of 
Ag* decreases; therefore, a compromise must be reached 
between (1) improved sensitivity, and (2) deteriorating 
signal-to-noise ratio. Initially, a 1.9 nM concentration of 
Ag* was chosen and 20 µL of 1:500 Ab in 3.0 mL total volume 
bound approximately 50% of this concentration of Ag*. The 
concentration of Ag* was later increased to 3.5 nM to 
improve the S/N ratio and the amount of Ab added was 
increased accordingly. Increasing the concentration of Ag* 
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Volume of 1/500 Ab added (uL) 
Figure 30. Antibody Dilution Profile, with Fluor-
escence Lifetime Plotted as a Function of 
Volume of 1:500 Ab Added for a Series of 
Ag* Concentrations. 11. 6 nM ( El ) , 5. 0 nm 
( + ) , 1 • 9 nM ( • ) , 1 • 2 nM ( ¢ ) Ag* • 
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Figure 31 shows a plot of PRFI as a function of the ¢ 0 
for free Ag*, 100% bound Ag* and a calibration blank, which 
contained 1.9 nM Ag*, 20 pL of 1:500 Ab, and no Ag. All 
three solutions have phase maxima at a ¢0 setting of around 
D 
115 . The observed phase angle difference between the free 
D 
and bound Ag* was 3.84 , which corresponds to a lifetime 
difference of 0.36 ns. This is consistent with the lifetime 
differences that were obtained from direct lifetime 
determinations (Figure 30). 
The PRFI intensity ratio of the 60 nM standard to the 
calibration blank for 3.5 nM Ag* and 35 pL of 1:500 Ab as a 
function of 4' 0 is shown in Figure 32. A¢ 0 of 45° gave the 
highest intensity ratio. At d:> 0 settings on either side of 
0 . 
45 , a decrease in the intensity difference between the 
standard and the blank was seen. 
Calibration curves were produced by plotting the ratio 
of the intensities (PRFI or steady-state) of each standard 
solution to that of the calibration blank as a function of 
the Ag concentration. Use of the intensity ratio helped to 
minimize the effects of variations in different sets of 
standard solutions and reagents, and of day-to-day 
variations in the tuning of the fluorometer. The cali-
bration curves were fit with a third-order polynomial 
function. Each of the curves shown in Figures 33 and 34 is 
the average of four curves, generated from triplicate 
measurements of each standard in the 100 average mode. The 
pooled standard deviation and relative standard deviations 
3000 
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Figure 31. Phase Angle Diagram in Which Rel-
ative PRFI of 1.9 nM Ag* in the 
Presence ( + ) and Absence (a ) 
of Ab is Plotted as a Function 
of the Detector Phase Angle 
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Figure 32. Ratio of the PRFI of Ag* in the 
Presence of Ag (60 nM) to the 
PRFI in the Absence of Ag when 
CA * = 3.5 nM and Vol.~b = 




for each type of calibration curve studied are shown in 
Table XIV, which also shows the estimated limit of detection 
if it was determined. The calibration curve isn't linear 
between the lowest standard and the calibration blank and 
the third-order polynomial function was unable to fit a line 
between these two points without distorting the rest of the 
curve. The nonlinearity is probably due to two factors. 
First, because the intensity ratio is used, the blank value 
is equal to 1.00 by definition. Second, immunoassay 
calibration curves are typically "S" shaped and thus the 
curve should be expected to level out as the concentration 
of Ag approaches zero. This appears to be happening 
somewhere between the 1.0 nM Ag standard and the blank. No 
other standards were run between these points so the curve 
is hard to fit in this region. Because of the nonlinearity, 
the limit of detection was estimated from the signal of the 
lowest standard plus three times its standard deviation. 
The actual detection limit is likely to be lower than this 
value but it can be used as an upper estimate. 
Effects of the Ag* concentration on the linear range 
and shape of the calibration curve are shown in Figure 33. 
Increasing the Ag* concentration from 1.9 to 3.5 nM 
increased the linear range and gave a calibration curve with 
a better fit. The pooled standard deviation decreased from 
0.028 to 0.020 intensity ratio units as the concentration 
of Ag* increased. These represent a coefficient of vari-
ation range of 2.8 to 2.5% and 1.9 to 1.5%, respectively, 
TABI,E XIV 
ANALYTICAL PARAMETERS FOR THE TYPES OF CALIBRATION CURVES STUDIED 
Type Cone. Ag *a Cone. TX-lOOa 
PRFS 1.7 nM 
PRFS 3.5 nM 
Steady State 3.5 nM 
PRFS in sera 3.5 nM 
PRFS in sera 3.5 nM 
PRFS % Free e 3.5 nM 
Concentration in cuvette. 







pooled sob RSDC LODd 
0.028 2.8 - 2.5 
0.020 1.9 - 1.5 1.6 nM 
0.034 2.9 - 2.5 
0.050 3.8 - 4.9 
0.024 1.6 - 2.0 2.6 nM 






Relative standard deviation (%) over the range of standard& used in the 
calibration curve. 
Estimated limit of detection. 
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Figure 33. Phase-Resolved ( • 1. 9 nM Ag*, r::l 3. 5 
nM Ag*) and Steady-State ( • 3. 5 nM 
Ag*) Calibration Curves. PRFI 
Ratio (as in·Figure 32) as a Func-
tion of Cone. Ag. Measurements 
Were Made at ~ D = 45", with 20 µl 
of Ab Added to the 1.9 nM Ag* Solu-




over the range of intensity ratios for the calibration 
curves. The estimated limit of detection for the 3.5 nM Ag* 
calibration curve was found to be 1.6 nM Ag. Figure 33 also 
shows a steady-state calibration curve at 3.5 nM Ag*. The 
steady-state calibration curve has lower sensi- tivity and a 
higher standard deviation than the PRFS calibration curve. 
Figure 34 shows phase-resolved calibration curves for 
phenobarbital in pooled human sera, at a 1:18,000 fold 
dilution. When the working standards were prepared in 
pooled human sera the imprecision of the data points 
increased. Increasing the amount of Triton X-100 in the 
buffer reduced this effect. However, increasing the concen-
tration of TX-100 also decreased the intensity ratio of the 
standards, which led to a decrease in the sensitivity. The 
intensity ratio of a 65 nM Ag standard was found to decrease 
gradually from 1.25 to 1.14 over a TX-100 concentration 
range of 0.010% (0.20 mM) to 0.100% (1.58 mM). When cali-
bration curves were run with 0.075% TX-100 added to the 
buffer, the pooled standard deviation decreased from 0.050 
to 0.024 intensity ratio units as shown in Table XIV. The 
relative standard deviation decreased correspondingly from 
~5% to N2%. The detection limit for the calibration curves 
with 0.075% TX-100 was estimated to be 2.6 nM Ag from the 
signal of the lowest standard plus three times its standard 
deviation. This value corresponds to a concentration of 
10.9 µg/ml in the undiluted sample. 
1.3 
0 - 1.2 as a: 
>--UI 
c: 
Cl) 1.1 -c: 
1.0-+-~-,~~--~--..~~....-~---~~--~--~--
0 20 40 60 80 
Cone. Ag* (nM) 
Figure 34. Effect of TX-100 on Phase-Resolved 
Calibration Curves of Ag in 1:18,000 
Dilution of Pooled Human Sera. PRFI 
ratio (as in Figure 32) as a function 
of Cone. Ag. Measurements were made 
at $ D = 45 , with Cone. Ag* = 3.5 nM, 
and 3 5 J.11 1 : 5 0 0 Ab. 0. 010 % ( • ) , · 
0 • 0 7 5 % ( El ) TX -10 0 • 
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The effect of the dilution factor of the pooled human 
sera on the intensity ratio of the calibration standards was 
also studied. As seen in Figure 35, the intensity ratio of 
the standards tends to decrease, as the level of sera in the 
calibration standards is increased. The lowest concen-
tration standards show little or no change in intensity 
ratio. As the concentration of Ag in the standards 
increases, the pooled sera has a proportionately greater 
effect on the intensity ratio. However, if a lower 
detection limit is desired, the dilution factor of the 
immunoassay could be decreased without significantly adverse 
effects on the low range of the calibration curve. 
Two phenobarbital test solutions of differing 
concentrations of Ag were prepared. The results of the 
determination of phenobarbital in these test solutions are 
shown in Table XV. Three replicates of each solution were 
analyzed and the mean for each solution was reported. 
Conclusions 
The differences in the fluorescence intensities of the 
free and Ab-bound labelled phenobarbital are much larger 
than those found in the previous PRFIA of phenobarbital (7). 
The change in the fluorescence lifetimes is also larger. 
Previously, only a small intensity difference and a lifetime 
difference of 0.10 ns was reported. In the current system 
there is about a 50% change in intensity and a lifetime 
difference of 0.36 ns. The previous PRFIA used reagents 
1.15 
0 -tU 1.10 a: 
>--UJ 1.05 c: 
Cl) -c: 
1.00 
0 5 1 0 1 5 
Cone. Ag (nM) 
Figure 35. Effect of Pooled Sera Dilution 
Factor on the Intensity Ratio 
of Calibration Standards. PRFI 
ratio (as in Figure 32) as a 
function of Cone. Ag for pooled 
sera dilution factors of ~ 
1:18,000, • 1:9,000, • 1:6000. 
Solution conditions: 3.5 nM Ag*, 




DETERMINATION OF UNKNOWN TEST SOLUTIONS 





1 13.3 nM 13.4 nM 0.8 1. 7 
2 50.0 nM 51.1 nM 2.2 1.3 
avg. 1.5 1.5 
Concentration added to cuvette. 
Experimentally determined value, average of three 
identically prepared solution, concentration in cuvette. 
Relative error of determination (%) for the mean 
concentration. 
Relative standard deviation (%) of the three replicates 
analyzed. 
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from a FIA kit that was commercially avaliable at that time. 
The current PRFIA uses labelled phenobarbital prepared in 
situ, in which the fluorescein moiety was attached to the 
para position of the aromatic ring of phenobarbital. The 
anti-phenobarbital antibody preparation, purchased from 
Cambridge Medical Diagnostics, was raised by injecting 
animals with a preparation of phenobarbital attached to a 
carrier molecule via the aromatic ring of phenobarbital. 
Thus, the label is unlikely to interfere with antibody 
binding to the labelled phenobarbital. 
The method of data analysis in the previous PRFIA (86} 
involved measuring the PRFI of each standard or sample at 
five different detector phase angles and generating a series 
of linear simultaneous equations. The series of equations 
was "solved" for the fractions of free and bound Ag* by 
using a Gauss-Newton iterative procedure on a microcomputer. 
The PRFIA calibration curve for phenobarbital was generated 
by plotting the % Free Ag* versus Ag concentration, followed 
by third-order polynomial fitting. This multiple 
phase-angle approach involves much more data collection and 
analysis than the current PRFIA. In order to compare the 
current system of reagents to the previous PRFIA, data were 
collected and analyzed in an analogous manner using two 
detector phase angles. The results are shown iri Table XIV. 
The detection limit for the old method was lower than the 
detection limit for the intensity ratio calibration curve, 
but a data point for the calibration blank was included in 
141 
the fit since a nontrivial value could be obtained using the 
multiple phase-angle approach. However, the mutiple 
phase-angle approach is not very amenable to automation. 
The current PRFIA could be easily automated using flow 
injection analysis. Serum samples are generally better 
behaved in flow systems, so it may also be possible to 
reduce the TX-100 concentration in the flow system in order 
to get higher sensitivity and a lower detection limit. 
CHAPTER VI 
CONCLUSIONS 
Homogeneous phase-resolved fluoroimmunochemical deter-
minations are advantageous in that they do not require a 
separation step or any other special sample handling tech-
niques. They are also the only FIA which uses fluorescence 
lifetime selectivity as the basis of homogeneous detection. 
The first PRFIA for haptens (86) involved fairly complicated 
and time-consuming data collection and analysis; which was 
required because there was very little difference in the 
fluorescence intensity and lifetime between the free and 
antibody-bound species. One of the main advantages of homo-
geneous FIAs is that they are usually easliy automated. The 
data collection and analysis scheme of the first PRFIA, in 
all practicality, precludes its automation. In order to 
better demonstrate the applicability of PRFS to immmuno-
assays for the determination of haptens, a simplified PRFIA 
with a larger change in signal between the free and bound 
labelled antigen was needed. 
This work decribes the attempts that were made to 
improve the discrimination between the Ag* and Ag*-Ab. The 
first section focused on the use of micelles and cyclo-
dextrins (auxillary binding reagents) to increase the 
142 
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difference in fluorescence signals. It was thought that the 
auxillary binding reagents might associate with the free Ag* 
and not with Ag*-Ab, thereby increasing the difference 
between their fluorescence signals. Unfortunately, the 
micelles and cyclodextrins associate with both Ag* and 
Ag*-Ab. The auxillary binding reagents decreased the inten-
sity ratio of free Ag* to Ag*-Ab, relative to the intensity 
ratio in buffer. The micelles and ~-CD also decreased the 
lifetime difference between the free Ag* and Ab-Ag*. The 
~-CD, on the other hand, increased the lifetime difference 
by about 0.05 ns. When the two effects are considered 
together, no gain in the ability to discriminate between Ag* 
and Ag*-Ab was found with ~-CD. The micelles may be useful 
with other haptens or labels; ~-CD would probably be useful 
if the aromatic ring of phenobarbital was accessable to it, 
perhaps by labelling via the ethyl group. 
The second part of this work involved the optimization 
of the experimental conditions and reagents used in the 
PRFIA of phenobarbital. The effects of several different 
antibody preparations on Ag* were studied. It was found 
that the intensity and lifetime differences could be 
increased dramatically by judicious choice of the antibody 
preparation. Because of the larger differences between the 
signals of Ag* and Ag*-Ab, a simplified data collection and 
analysis scheme was implemented. The automation of this new 
PRFIA for phenobarbital should be fairly simple using an 
unsegmented continuous-flow system. 
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